tolvaptan has been researched along with Heart Failure in 356 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 65 (18.26) | 29.6817 |
| 2010's | 223 (62.64) | 24.3611 |
| 2020's | 68 (19.10) | 2.80 |
| Authors | Studies |
|---|---|
| Hioki, H; Ishibashi, R; Kataoka, A; Kozuma, K; Kuwabara, M; Mitsui, M; Nagura, F; Uno, K; Watanabe, Y; Yokoyama, N | 1 |
| Hirano, T; Kim, S; Sato, N; Uno, S; Yamasaki, Y | 1 |
| Doi, T; Fukahara, K; Imamura, T; Kinugawa, K; Yamashita, S; Yokoyama, S; Yoshimura, N | 1 |
| Ishikawa, S; Murohara, T; Shibata, R; Takemoto, K; Uemura, Y; Watarai, M | 1 |
| Fukuda, K; Kohno, T; Kohsaka, S; Nagatomo, Y; Shiraishi, Y; Yamazaki, Y; Yoshikawa, T | 1 |
| Iwasaki, YK; Kubota, Y; Matsuda, J; Seki, T; Shimizu, W; Tokita, Y | 1 |
| Chino, S; Endo, Y; Fukuoka, H; Hachiya, R; Ichikawa, S; Kuroki, Y; Miyazaki, H; Mochizuki, Y; Omomo, Y; Ota, M; Shibakai, M; Shinke, T; Toyosaki, E | 1 |
| Iwata, S; Nakagawa, K; Nishiura, T; Okada, M; Sakai, H; Tokuno, S; Yamaki, M | 1 |
| Ikeda, S; Inoue, K; Kawakami, H; Nakao, Y; Saito, M; Yamaguchi, O | 1 |
| Fukumoto, Y; Shimozono, K | 1 |
| Ikari, Y; Matsumoto, S; Murakami, T; Nakamura, N; Nakazawa, G; Natsumeda, M; Ohno, Y; Sakai, K; Shinozaki, N | 1 |
| Bagga, A; Hari, P; Meena, J; Sinha, A | 1 |
| Egami, Y; Kawamura, A; Kawanami, S; Matsuhiro, Y; Matsunaga-Lee, Y; Nakamura, H; Nishino, M; Okamoto, N; Sugae, H; Tanaka, A; Tanouchi, J; Tsuda, M; Ukita, K; Yano, M; Yasumoto, K | 1 |
| Hirai, M; Kamitani, H; Kato, M; Kinugasa, Y; Matsubara, K; Nakamura, K; Takami, A; Yamamoto, K; Yanagihara, K | 1 |
| Hirano, T; Kim, S; Kinugawa, K; Nakata, E | 1 |
| Amioka, N; Endo, T; Iida, T; Ito, H; Kishinoue, T; Matsuo, N; Mori, H; Nakamura, K; Nakano, Y; Onishi, N; Takaishi, A; Tanimoto, M; Ueeda, M; Yamaji, T; Yasuhara, K | 1 |
| Fujiwara, A; Haze, T; Hirawa, N; Katsumata, M; Kawano, R; Kobayashi, Y; Komiya, S; Ohki, Y; Ozawa, M; Saka, S; Suzuki, S; Tamura, K | 1 |
| Bianchetti, MG; Lava, SAG; Leoni-Foglia, C; Milani, GP; Piffer, A; Simonetti, GD | 1 |
| Dobashi, S; Hisatake, S; Ikeda, T; Kabuki, T; Kiuchi, S; Murakami, Y; Oka, T; Sano, T | 1 |
| Akutsu, S; Hoshikawa, K; Kawakami, J; Maekawa, Y; Mino, Y; Naito, T; Saotome, M | 1 |
| Kim, S; Kurita, Y; Sato, N; Uno, S | 1 |
| Imamura, T; Kakeshita, K; Kinugawa, K; Onoda, H | 1 |
| Han, D; Shang, W; Zhang, Y | 1 |
| Imamura, T; Nakagawa, Y | 1 |
| Kinugasa, Y; Takami, A; Yamamoto, K | 1 |
| Amioka, M; Kinoshita, H; Matsumura, H; Morishima, N; Nakano, Y; Sairaku, A; Sanada, R | 1 |
| Hosomi, K; Kawabata, K; Uno, T; Yokoyama, S | 1 |
| Duan, X; He, Y; Wu, Q; Yan, F; Zhu, H | 1 |
| Aihara, M; Kinugawa, K; Matsukawa, M; Nakamura, Y; Sano, H | 1 |
| Cui, M; Wang, HY; Zhao, J; Zhu, ZY | 1 |
| Kokubu, N; Kouzu, H; Nagano, N; Noto, T; Osanami, A; Tanno, M | 1 |
| Kawano, M; Kurozumi, A; Nakano, M; Nishio, S; Tajima, E; Takimura, H; Takimura, Y; Taniguchi, R; Tsukahara, R; Tsuzuki, I; Yamaguchi, Y | 1 |
| Fujioka, H; Imamura, T; Kakeshita, K; Kinugawa, K; Koike, T; Yamazaki, H | 2 |
| Li, J; Yin, C; Yuan, L | 1 |
| Kawano, M; Nakano, M; Nishio, S; Tajima, E; Takimura, H; Takimura, Y; Taniguchi, R; Tsukahara, R; Tsuzuki, I; Yamaguchi, Y | 1 |
| Amano, T; Kato, T; Matsuura, K; Nakano, Y; Okamoto, H; Oonishi, M; Saito, Y; Yasuda, Y | 1 |
| Hasegawa, M; Hayashi, H; Inaguma, D; Koide, S; Ogata, S; Tagaya, T; Takahashi, K; Tsuboi, N; Yuzawa, Y | 1 |
| Chen, H; Gao, J; Li, H; Li, Y; Mi, Z; Pan, Y | 1 |
| Fujimori, K; Fushimi, K; Miyazaki, D; Tarasawa, K | 1 |
| Aoyama, D; Morishita, T; Nakano, A; Nomura, R; Sato, Y; Shimizu, T; Tada, H; Uzui, H | 1 |
| Guo, M; Hao, M; Yang, J; Zhang, L | 1 |
| Fukuta, Y; Inomata, T; Kinugawa, K; Sato, N; Shimakawa, T; Yasuda, M | 2 |
| Chung, B; Fujino, T; Imamura, T; Jeevanandam, V; Kalantari, S; Kim, G; LaBuhn, C; Narang, N; Nguyen, A; Nitta, D; Raikhelkar, J; Rodgers, D; Sarswat, N; Sayer, G; Smith, B; Uriel, N | 1 |
| Akutsu, S; Hoshikawa, K; Kawakami, J; Maekawa, Y; Naito, T; Saotome, M | 2 |
| Chen, S; Du, R; Han, S; Li, J; Liu, M; Wang, L; Zhang, Q | 1 |
| Bhatt, AS; Butler, J; Fonarow, GC; Greene, SJ; Konstam, MA; Patel, RB; Subacius, HP; Vaduganathan, M; Zannad, F | 1 |
| Cox, ZL; Hung, R; Lenihan, DJ; Testani, JM | 1 |
| Nishi, H | 1 |
| Hayashida, K; Hioki, H; Izumo, M; Jujo, K; Kataoka, A; Kawashima, H; Kozuma, K; Mizutani, K; Nakashima, M; Nakazawa, G; Nara, Y; Nishihata, Y; Tanaka, J; Watanabe, Y; Yamamoto, M | 1 |
| Abe, M; Fujita, T; Fukunami, M; Furukawa, Y; Kawahira, M; Kawai, T; Kawasaki, M; Kayama, K; Kikuchi, A; Kimura, T; Morita, T; Nakamura, J; Sakamoto, D; Seo, M; Tamaki, S; Tamura, Y; Tanabe, K; Ueda, K; Yamada, T; Yamamoto, K | 1 |
| Fujii, K; Kin, H; Matsumura, K; Otagaki, M; Park, H; Shiojima, I; Sugiura, T; Takahashi, H; Yamamoto, Y; Yokoi, M; Yoshioka, K | 1 |
| Jin, Q; Luo, X; Wu, Y | 1 |
| Griffin, M; Konstam, MA; McCallum, W; Sarnak, MJ; Testani, JM; Tighiouart, H; Udelson, JE | 1 |
| Elkayam, U; Fong, MW; Grazette, LP; Han, EE; Kuo, A; Lou, M; Mehra, A; Ng, TMH; Upadhyay, RY; Yoon, AJ | 1 |
| Amitani, K; Iha, H; Imura, H; Ishihara, S; Ishikawa, M; Ishizuka, A; Ito, Y; Kikuchi, A; Kobayashi, N; Maruyama, Y; Mitsuishi, T; Nakama, K; Nakamura, S; Nohara, T; Ohkuma, S; Omote, T; Sato, N; Shigihara, S; Shimizu, W; Sone, M; Takagi, K; Takahashi, N; Tokuyama, H; Yamamoto, E | 1 |
| Attia, H; El-Shabrawy, M; Emad Aboulhoda, B; Emam, M; Mishriki, A; Wanas, H | 1 |
| Hu, J; Jiang, L; Li, M; Wan, Q; Yuan, F; Zhang, Y; Zhou, J | 1 |
| Fukuoka, H; Hoshida, S; Inoue, S; Inui, H; Minamisaka, T; Mine, K; Shinoda, Y; Tachibana, K; Ueda, K; Ueno, K | 1 |
| Bhatt, AS; Konstam, MA; Yanamandala, M | 1 |
| Mori, T; Shinoda, R; Shinoda, Y; Yoshimura, T | 1 |
| Endo, A; Kagawa, Y; Morita, Y; Ouchi, T; Sato, H; Tanabe, K; Watanabe, N; Yamaguchi, K | 1 |
| Fujimoto, K; Fujiwara, R; Horio, T; Izumiya, Y; Kasayuki, N; Matsuoka, Y; Nakamura, H; Nakao, K; Sakamoto, Y; Yokouchi, G; Yoshimura, R; Yoshiyama, M | 1 |
| Akabane, M; Ishii, Y; Miki, K; Nakamura, Y; Yokoyama, T | 1 |
| Adachi, T; Hitomi, Y; Kagami, K; Masaki, N; Nagatomo, Y; Namba, T; Toya, T; Yada, H; Yasuda, R; Yukino, M; Yumita, Y | 1 |
| Imai, S; Kashiwagi, H; Miyai, T; Momo, K; Sato, Y; Sugawara, M; Takekuma, Y | 1 |
| Fernández-Ruiz, I | 1 |
| Momomura, SI | 1 |
| Gustafsson, F; Vishram-Nielsen, JK | 1 |
| Boklage, S; Kamat, S; Mladsi, D; Ramamohan, V; Ronquest, N | 1 |
| Adachi, S; Arimura, T; Fujimi, K; Iwata, A; Kitajima, K; Kuwano, T; Miura, SI; Morii, J; Morito, N; Nishikawa, H; Saku, K; Shiga, Y; Yahiro, E | 1 |
| Huang, WL; Wang, HB; Xiong, XL; Yang, J; Yang, Y; Zhang, YF | 1 |
| Daida, H; Hiki, M; Kasai, T; Kato, T; Miyauchi, K; Miyazaki, T; Murata, A; Negoro, K; Shimizu, M; Suda, S; Takasu, K; Yatsu, S | 1 |
| Kida, K | 1 |
| Damman, K; Fujii, H; Fukamizu, S; Goldsmith, SR; Kagiyama, N; Kitai, T; Matsue, Y; Nishioka, T; Noda, M; Onishi, Y; Ono, Y; Satoh, Y; Sugi, K; Suzuki, M; Ter Maaten, JM; Torii, S; van der Meer, P; Voors, AA; Yamaguchi, S; Yoshida, K | 1 |
| Dobashi, S; Fujii, T; Hisatake, S; Ikeda, T; Kabuki, T; Kiuchi, S; Takashi, O | 1 |
| Cai, L; Wang, C; Xiong, B | 1 |
| Aydın Kaderli, A; Aydınlar, A; Baran, İ; Çavuşoğlu, Y; Gül, BC; Güllülü, S; Özdemir, B; Sağ, S; Yıldız, A | 1 |
| Fujii, H; Fukamizu, S; Goldsmith, SR; Kagiyama, N; Kitai, T; Matsue, Y; Nishioka, T; Noda, M; Onishi, Y; Ono, Y; Satoh, Y; Sugi, K; Suzuki, M; Torii, S; Yamaguchi, S; Yoshida, K; Yoshioka, K | 1 |
| Isobe, M; Kamiyama, M; Masumura, M; Nomoto, H; Ohno, M; Oumi, T; Sakakibara, A; Satoh, Y; Sugiyama, T; Suzuki, M; Takahashi, Y; Yabe, K; Yamashita, S | 1 |
| Abdulhadi, B; Mezue, K; Rangaswami, J | 1 |
| Anzai, H; Fukui, R; Iijima, R; Kobayashi, N; Kogame, N; Niikura, H; Takenaka, H | 1 |
| Kubota, T; Matsukawa, R; Meno, H; Okabe, M; Yamamoto, Y | 1 |
| Ako, J; Ikeda, Y; Inomata, T; Izumi, T; Kida, K; Kumagai, Y; Sato, N; Shibagaki, Y; Shinagawa, H | 1 |
| Imai, R; Ishikawa, S; Koyasu, M; Murohara, T; Ozaki, Y; Shibata, R; Takemoto, K; Teraoka, T; Uchikawa, T; Uemura, Y; Watanabe, T; Watarai, M | 1 |
| Hiasa, G; Hosokawa, S; Kawada, Y; Kawamura, G; Kazatani, Y; Kinoshita, M; Kosaki, T; Matsuoka, H; Okayama, H; Shigematsu, T; Takahashi, T; Yamada, T | 1 |
| Chen, TT; Chen, YC; Lin, HH; Tarng, DC; Tu, YK; Wu, MY; Wu, YC | 1 |
| Hamano, T; Isaka, Y; Iwatani, H; Kimura, Y; Minami, S; Mizui, M | 1 |
| Amitani, K; Imura, H; Ishihara, S; Ishikawa, M; Kikuchi, A; Maruyama, Y; Nakama, K; Omote, T; Sato, N; Shimizu, W; Sone, M; Takagi, K; Takahashi, N; Tokuyama, H | 1 |
| Dobashi, S; Fujii, T; Hisatake, S; Ikeda, T; Kabuki, T; Kiuchi, S; Oka, T | 2 |
| Hagiwara, N; Hamada, K; Jujo, K; Kogure, T; Saito, K | 1 |
| Akashi, YJ; Inomata, T; Izumi, T; Kida, K; Sato, N; Shibagaki, Y; Tominaga, N | 2 |
| Kinugawa, K; Kugai, T; Nakamura, M; Sunagawa, O | 1 |
| Hamada, M; Ikeda, S; Kadota, H; Miyazaki, S; Ogimoto, A; Ohshima, K; Shimizu, H | 1 |
| Jolobe, OMP | 1 |
| Amin, AN; Chase, SL; Harmon, AL; Kamat, SA; Ortendahl, JD; Stellhorn, RA; Sundar, SV | 1 |
| Amano, T; Ando, H; Mizuno, T; Mukai, K; Murotani, K; Nakano, Y; Niwa, T; Takashima, H; Wakabayashi, H; Waseda, K; Watanabe, A | 1 |
| Kahraman, F; Yılmaz, AS | 1 |
| Kinugawa, K; Nakamura, M; Sunagawa, O | 1 |
| Bhasin, B; Bohm, NM; Crawford, R; Kelley, D; Morris, JH; Nemecek, BD; Nietert, PJ; Velez, JCQ | 1 |
| Liu, XM; Zhang, ZG | 1 |
| Ishii, H; Izumi, K; Kamiya, H; Kawamura, Y; Murohara, T; Oguri, M; Ohguchi, S; Takahara, K; Takahashi, H; Yokoi, Y | 1 |
| Chung, E; McGill, D; Sen, J | 1 |
| Inomata, T; Kinugawa, K; Sato, N; Shibasaki, Y; Shimakawa, T; Yasuda, M | 1 |
| Hoshiyama, A; Kamata, Y; Masaki, T; Shichiri, M; Takada, T; Toki, T | 1 |
| Ehara, S; Kawase, Y; Matsumoto, K; Nakamura, Y; Otsuka, K | 1 |
| Ambrosy, AP; Butler, J; Chatterjee, NA; Gheorghiade, M; Greene, SJ; Konstam, MA; Maggioni, AP; Mentz, RJ; O'Connor, CM; Patel, RB; Subacius, H; Swedberg, K; Udelson, JE; Vaduganathan, M; Zannad, F | 1 |
| Chase, S; Dasta, JF; Lin, J; Lingohr-Smith, M; Sundar, S | 1 |
| Chibnall, JT; Godishala, A; Goff, ZD; Hauptman, PJ; Joseph, SM; Shuster, JE; Vidic, A | 1 |
| Ikeda, T; Kiuchi, S | 1 |
| Ako, J; Ikeda, Y; Inomata, T; Izumi, T; Kida, K; Sato, N; Shibagaki, Y | 1 |
| Suzuki, S; Takeishi, Y | 1 |
| Inomata, T; Kinugawa, K; Sato, N | 1 |
| Matsumura, K; Morishita, S; Otagaki, M; Shiojima, I; Takagi, M; Takahashi, H; Takehana, K; Taniguchi, N; Yamamoto, Y; Yoshioka, K | 1 |
| Imamura, T; Kinugawa, K | 4 |
| Hada, T; Kawano, M; Muramatsu, T; Nakano, M; Nishio, S; Takimura, H; Takimura, Y; Tsukahara, R; Yabe, T | 1 |
| Aonuma, K; Chiba, H; Ishizu, T; Namekawa, M; Sai, S; Seo, Y | 1 |
| Hiramatsu, E; Ito, C; Otsuka, Y; Shinjo, H; Takeda, A; Tanaka, A; Watanabe, Y | 1 |
| Joseph, J; Joseph, L; Zhang, L | 1 |
| Hirose, T; Kinugasa, S; Mori, T | 1 |
| Gao, WQ; Meng, XD; Sun, Z | 1 |
| Berei, TJ; Fine, M; Gunderson, EG; Lillyblad, MP; Vardeny, O | 1 |
| Hoshikawa, K; Kawakami, J; Maekawa, Y; Naito, T; Saotome, M | 1 |
| Hioki, H; Kataoka, A; Kawashima, H; Kozuma, K; Mitsui, M; Nagura, F; Nakashima, M; Nara, Y; Watanabe, Y; Yokoyama, N | 1 |
| Imamura, T | 1 |
| Li, GS; Li, T | 1 |
| Fukuoka, Y; Hasegawa, K; Ikeda, H; Ishida, K; Kaseno, K; Miyazaki, S; Morishita, T; Mukai, M; Nakano, A; Sato, Y; Shiomi, Y; Tada, H; Tama, N; Uzui, H | 1 |
| Kajimoto, K; Otsubo, S | 1 |
| Hatano, M; Imamura, T; Inaba, T; Kato, N; Kinugawa, K; Komuro, I; Kyo, S; Maki, H; Minatsuki, S; Muraoka, H; Ono, M; Shiga, T; Yao, A | 1 |
| Barnes, AP; Gonzalez, A; Koch, JD; Leonard, D; Quigley, R; Regen, RB; Zawodniak, K | 1 |
| Hori, M | 2 |
| Murasawa, T; Ohno, D; Otsuka, T; Sakai, Y; Sato, N; Tsuruoka, S | 1 |
| Ishikawa, M; Ishimitsu, T; Kobayashi, N; Onoda, S; Sugiyama, F | 1 |
| Hatano, M; Hosoya, Y; Imamura, T; Inaba, T; Kato, N; Kinugawa, K; Komuro, I; Kyo, S; Maki, H; Minatsuki, S; Muraoka, H; Ono, M; Shiga, T; Takahashi, M; Yao, A | 1 |
| Goldsmith, SR | 5 |
| Mager, DE; Mallikaarjun, S; Shoaf, SE; Van Wart, SA | 2 |
| Ambrosy, AP; Butler, J; Filippatos, G; Gheorghiade, M; Greene, SJ; Konstam, MA; Maggioni, AP; Mentz, RJ; Nodari, S; Subacius, H; Vaduganathan, M | 1 |
| Casscells, SW; Gheorghiade, M; Maggioni, AP; Miller, AB; Pang, PS; Payvar, S; Reid, KJ; Spertus, JA; Swedberg, K; Zannad, F | 1 |
| Imamura, T; Kinugawa, K; Komuro, I | 2 |
| Fujiki, H; Hanatani, A; Iwao, H; Izumi, Y; Miura, K; Nakamura, Y; Osada-Oka, M; Shimada, K; Shiota, M; Yamazaki, T; Yoshiyama, M | 1 |
| Fujii, H; Matsue, Y; Nagahori, W; Nishioka, T; Noda, M; Okishige, K; Onishi, Y; Ono, Y; Sakurada, H; Satoh, Y; Sugi, K; Suzuki, M; Takahashi, A; Tejima, T; Torii, S; Yamaguchi, S; Yoshida, K | 1 |
| Abe, Y; Kubota, I; Kunii, H; Nakazato, K; Ohwada, T; Saito, T; Saitoh, S; Sugimoto, K; Suzuki, H; Suzuki, S; Takeishi, Y; Yamaki, T; Yoshihisa, A | 3 |
| Goldsmith, SR; Kalra, A; Maharaj, V | 1 |
| Hatano, M; Imamura, T; Inaba, T; Kato, N; Kinugawa, K; Komuro, I; Maki, H; Minatsuki, S; Muraoka, H; Yao, A | 2 |
| Chida, M; Ito, S; Kiyomoto, H; Kodama, M; Koizumi, K; Miyazaki, M; Mori, T; Oba, I; Ogawa, S; Saito, M; Sato, H; Shimanuki, M; Tanno, M | 1 |
| Iwao, H; Izumi, Y; Miura, K | 1 |
| Asai, K; Hata, N; Kobayashi, N; Matsushita, M; Okazaki, H; Shimizu, W; Shinada, T; Shirakabe, A; Tomita, K; Tsurumi, M; Yamamoto, M; Yamamoto, Y; Yokoyama, S | 1 |
| Dohi, K; Ito, M | 2 |
| Bonow, RO; Butler, J; Chioncel, O; Gheorghiade, M; Greene, SJ; Harinstein, ME; Konstam, MA; Maggioni, AP; Subacius, H; Swedberg, K; Vaduganathan, M; Wilcox, JE; Yancy, CW; Zannad, F | 1 |
| Inomata, T; Iwatake, N; Kinugawa, K; Mizuguchi, K; Sato, N; Shimakawa, T | 1 |
| Fukada, Y; Hirota, M; Hoshino, J; Isomura, T; Kondo, T; Takahashi, Y | 1 |
| Almenar-Bonet, L; Martínez-Dolz, L; Rodríguez-de Muñoz, YM; Rodríguez-Serrano, M; Salvador-Sanz, A; Sánchez-Lázaro, IJ | 1 |
| Esteban-Fernández, A; García-López, M; Gavira-Gómez, JJ; Lavilla-Royo, FJ; Salterain-Gonzalez, N | 1 |
| Higo, T; Imamura, T; Kinugawa, K; Kinugawa, S; Komuro, I; Ohtani, T; Sakata, Y; Sunagawa, K; Tsutsui, H | 1 |
| Bart, BA; Burnett, J; Goldsmith, SR | 1 |
| Maggioni, AP | 1 |
| Formiga, F; Morales-Rull, JL; Trullàs, JC | 1 |
| Chivite, D; Corbella, X; Formiga, F | 1 |
| Fujino, T; Hatano, M; Imamura, T; Inaba, T; Kinugawa, K; Komuro, I; Maki, H; Yao, A | 1 |
| Sato, N | 1 |
| Han, E; Kang, HJ; Kim, HL; Lee, EK; Lee, MY; Park, SY | 1 |
| Hata, H; Iida, M; Osaka, S; Sezai, A; Shiono, M; Yoshitake, I | 1 |
| Abe, T; Kajimoto, K | 1 |
| Adams, KF; Lin, TE; Patterson, JH | 1 |
| Akashi, YJ; Kida, K; Kimura, K; Matsumoto, N; Miyake, F; Shibagaki, Y; Tominaga, N | 2 |
| Ambrosy, AP; Butler, J; Chioncel, O; Gheorghiade, M; Givertz, MM; Greene, SJ; Konstam, MA; Maggioni, AP; Mentz, RJ; Senni, M; Subacius, HP; Swedberg, K; Vaduganathan, M; Zannad, F | 1 |
| Amaha, M; Matsumura, D; Nakamura, T; Nomura, M; Ono, Y; Sato, E; Ueda, Y; Yamagishi, H | 1 |
| Doi, K; Imamura, T; Kinugawa, K; Nangaku, M; Noiri, E; Shimizu, K; Yahagi, N | 1 |
| Hirano, D; Ida, H; Ito, A; Kakegawa, D; Miwa, S; Yamada, A | 1 |
| Butler, J; Campia, U; Chioncel, O; Gheorghiade, M; Khan, SS; Konstam, MA; Maggioni, AP; Nodari, S; Rossignol, P; Senni, M; Subacius, H; Swedberg, K; Vaduganathan, M; Zannad, F | 1 |
| Bando, K; Inomata, T; Kinugawa, K; Mizuguchi, K; Sato, N; Shimakawa, T; Yasuda, M | 1 |
| Yamamoto, K | 1 |
| Acaban, MB; Arı, H; Kahraman, F | 1 |
| Hamano, T; Isaka, Y; Iwatani, H; Kawabata, H; Rakugi, H; Sakaguchi, Y; Yamamoto, R | 1 |
| Fukuda, K; Humbert, M; Kimura, M; Kuwana, M; Ono, T; Satoh, T; Takei, M; Tamura, Y | 1 |
| Hagiwara, N; Minami, Y; Okayama, D; Shiga, T; Suzuki, T; Tsuruoka, S | 1 |
| Asada, Y; Kitamura, K; Nishihira, K; Okubo, T; Yamaguchi, M | 1 |
| Fujimoto, S; Horii, M; Kawakami, R; Nakada, Y; Nakano, T; Okayama, S; Onoue, K; Saito, Y; Takeda, Y; Ueda, T; Uemura, S | 1 |
| Hashimoto, K; Ito, H; Kawai, Y; Kohno, K; Koide, Y; Miyaji, K; Miyoshi, T; Nakahama, M; Nakamura, K; Nishii, N; Tachibana, M; Terasaka, R; Toda, H; Tokioka, K; Wada, T; Watanabe, A; Yoshioka, R | 1 |
| Amemiya, K; Araki, H; Ebara, S; Hoshimoto, K; Igawa, W; Isomura, N; Kido, T; Ochiai, M; Okabe, T; Ono, M; Saito, S; Yakushiji, T; Yamamoto, MH; Yamashita, K | 1 |
| Akahoshi, Y; Fujiki, H; Ikeda, T; Iwanaga, Y; Miyazaki, S; Morooka, H; Watanabe, H | 1 |
| Cao, Y; Deng, S; Huang, J; Huang, Y; Qian, J; Rong, S; Tan, J; Wang, C; Xiong, B; Yao, Y; Zou, Y | 1 |
| Hatano, M; Imamura, T; Kimura, M; Kinoshita, O; Kinugawa, K; Nawata, K; Ono, M | 1 |
| Adams, KF; Cole, RT; Egnaczyk, GF; Felker, GM; Fiuzat, M; Gregory, D; Konstam, MA; Mentz, RJ; O'Connor, CM; Patel, CB; Udelson, JE; Wedge, P | 1 |
| Butler, J; Gheorghiade, M; Goldsmith, SR; Senni, M; Vaduganathan, M | 1 |
| Inukai, S; Ito, K; Kato, T; Nagasaki, R; Saitoh, S; Sato, N; Sugiura, T; Suzuki, K | 1 |
| Imai, R; Ishikawa, S; Iwamiya, S; Kato, T; Koyasu, M; Mitsuda, T; Miura, A; Miura, T; Murohara, T; Ozaki, Y; Shibata, R; Takemoto, K; Uchikawa, T; Uemura, Y; Watarai, M | 1 |
| Kubota, T; Matsukawa, R; Okabe, M; Yamamoto, Y | 1 |
| Hasegawa, T; Ikeda, U; Izawa, A; Kimura, K; Misawa, T; Momose, T; Morita, T; Motoki, H | 1 |
| Higashi, K; Honda, T; Ishikawa, S; Ishikawa, Y; Itoi, T; Kodama, Y; Masutani, S; Murakami, T; Ohuchi, H; Senzaki, H; Yamazawa, H | 1 |
| Katayama, I; Noguchi, K; Oosiro, N; Sirouzu, M; Tanaka, M; Yamabe, T; Yuji, D | 1 |
| Butler, J; Cook, TD; Fonarow, GC; Gheorghiade, M; Greene, SJ; Kalogeropoulos, AP; Konstam, MA; Maggioni, AP; Swedberg, K; Zannad, F; Zea, R | 1 |
| Ambrosy, AP; Bazari, H; Butler, J; Chioncel, O; Fonarow, GC; Gheorghiade, M; Greene, SJ; Konstam, MA; Maggioni, AP; Marti, CN; Mentz, RJ; Sato, N; Subacius, HP; Vaduganathan, M; Zannad, F | 1 |
| Fujii, H; Fukamizu, S; Goldsmith, SR; Kagiyama, N; Kitai, T; Matsue, Y; Nishioka, T; Noda, M; Onishi, Y; Ono, Y; Satoh, Y; Sugi, K; Suzuki, M; Torii, S; Yamaguchi, S; Yoshida, K | 2 |
| Nakamura, T; Node, K; Sato, E; Tanaka, A | 1 |
| Hashimoto, Y; Kagiyama, N; Kume, T; Matsue, Y; Matsumura, A; Okura, H; Suzuki, M; Yoshida, K; Yoshioka, K | 1 |
| Dohi, K; Fujimoto, N; Ito, M; Kumagai, N; Nakamori, S; Ogura, T; Sato, Y; Sugimoto, T; Sugiura, E; Takeuchi, T; Tanimura, M; Watanabe, K; Yamada, N | 1 |
| Ambrosy, AP; Butler, J; Gheorghiade, M; Katz, SD; Konstam, MA; Mecklai, A; Subačius, H | 1 |
| Anjaneyan, K; Doss, CR; George, M; Jena, A; Kanagesh, B; Rajaram, M; Ramaraj, B; Shanmugam, E | 1 |
| Ambrosy, AP; Butler, J; Chioncel, O; Gheorghiade, M; Greene, SJ; Khan, H; Konstam, MA; Maggioni, AP; Mentz, RJ; Subacuis, HP; Swedberg, K; Udelson, JE; Vaduganathan, M; Zannad, F | 1 |
| Al-Mohammad, A; Alskaf, E; Tridente, A | 1 |
| Bloomfield, DM; Cleland, JG; Cotter, G; Damman, K; Davison, B; Gheorghiade, M; Givertz, MM; Hillege, HL; Metra, M; O'Connor, CM; Ponikowski, P; Subacius, H; Teerlink, JR; Ter Maaten, JM; Valente, MA; van der Meer, P; van Veldhuisen, DJ; Voors, AA | 1 |
| Akaike, M; Bando, M; Bando, S; Hara, T; Ise, T; Iwase, T; Kadota, M; Kawabata, Y; Matsuura, T; Ogasawara, K; Sata, M; Soeki, T; Ueno, R; Wakatsuki, T; Yagi, S; Yamada, H; Yamaguchi, K | 1 |
| Doi, A; Hanatani, A; Iwata, S; Kitada, R; Matsumura, Y; Shibata, A; Sugioka, K; Takagi, M; Yoshiyama, M | 1 |
| Hirai, K; Inoue, K; Ishii, H; Itoh, K; Kadoiri, T; Moriwaki, H; Shimomura, T; Shimoshikiryo, T; Tsuji, D | 1 |
| Hori, H; Kono, T; Tanaka, H; Tayama, E; Ueda, T; Yamaki, Y | 1 |
| Nitta, D | 1 |
| Eguchi, A; Hirotani, S; Iwasaku, T; Mano, T; Masuyama, T; Naito, Y; Okuhara, Y | 1 |
| Imamura, T; Kinugawa, K; Komuro, I; Nitta, D | 1 |
| Starling, RC; Young, JB | 1 |
| Adams, KF; Cole, RT; Echols, M; Egnaczyk, GF; Felker, GM; Fiuzat, M; Gupta, D; Khouri, MG; Mentz, RJ; Monds, P; O'Connor, CM; Patel, CB; Roberts, R; Tauras, JM | 1 |
| Bando, K; Fukuta, Y; Inomata, T; Kinugawa, K; Sato, N; Shimakawa, T; Yasuda, M | 1 |
| Tesař, V | 1 |
| Ehara, Y; Fujikawa, T; Fujita, M; Fujiwara, A; Hirawa, N; Kagimoto, M; Katsumata, M; Kobayashi, M; Kobayashi, Y; Okuyama, Y; Saka, S; Sumida, K; Tamura, K; Toya, Y; Umemura, S; Yamamoto, Y; Yasuda, G; Yatsu, K | 1 |
| Amano, T; Ando, H; Mizuno, T; Mukai, K; Nakano, Y; Niwa, T; Takashima, H; Wakabayashi, H; Waseda, K; Watanabe, A | 1 |
| Abe, M; Fukuhara, E; Fukunami, M; Furukawa, Y; Ikeda, I; Iwasaki, Y; Kawasaki, M; Kikuchi, A; Kondo, T; Morita, T; Nakamura, J; Ozaki, T; Sato, Y; Seo, M; Tamaki, S; Yamada, T | 1 |
| Jung, MC; Kim, HJ; Kim, JK; Kim, SG; Lee, CM; Park, GH; Song, JW; Song, YR | 1 |
| Chandler, A; Dhingra, R; Dowling, D; Eisen, H; Fileccia, R; Gordon, P; Gregory, D; Gupta, D; Haught, WH; Kiernan, M; Konstam, JM; Konstam, MA; Korr, K; Massaro, JM; Mody, FV; Patten, R; Pressler, SJ; Romeling, M; Udelson, JE; Wagoner, L; Wedge, P | 1 |
| Yancy, CW | 2 |
| Ho, JE; Teerlink, JR | 1 |
| Farmakis, D; Filippatos, G; Gheorghiade, M; Kremastinos, DT; Parissis, J | 1 |
| Farmakis, D; Filippatos, G; Gheorghiade, M; Kremastinos, DT | 1 |
| Boerrigter, G; Burnett, JC; Costello-Boerrigter, LC | 2 |
| Francis, GS; Unzek, S | 1 |
| Whellan, DJ | 1 |
| Blair, JE; Burnett, JC; Cook, T; Gheorghiade, M; Grinfeld, L; Konstam, MA; Krasa, H; Maggioni, AP; Orlandi, C; Swedberg, K; Traver, B; Udelson, JE; Zannad, F; Zimmer, C | 1 |
| Cavalcante, JL; Gheorghiade, M; Khan, S | 1 |
| Gross, P; Herbrig, K; Marczewski, T | 1 |
| Lindenfeld, J | 1 |
| Blair, JE; Burnett, JC; Chen, CF; Gheorghiade, M; Grinfeld, L; Khan, S; Konstam, MA; Maggioni, AP; Ouyang, J; Swedberg, K; Udelson, JE; Zannad, F; Zimmer, CA | 1 |
| Dhalla, NS; Rehsia, NS | 1 |
| Haass, M | 1 |
| Boerrigter, G; Burnett, JC; Cataliotti, A; Costello-Boerrigter, LC; Harty, GJ | 1 |
| Allen, LA; Chan, PS; Dunlay, SM; Gheorghiade, M; Hauptman, PJ; Konstam, MA; Maggioni, AP; Reid, KJ; Spertus, JA; Swedberg, K; Zannad, F | 1 |
| Reilly, T; Schork, MR | 1 |
| Bahit, MC; Blair, JE; Carson, P; Cook, T; Gheorghiade, M; Haass, M; Hauptman, PJ; Konstam, MA; Metra, M; Miller, AB; O'Connor, CM; Oren, RM; Patten, R; Piña, I; Roth, S; Sackner-Bernstein, JD; Traver, B; Wedge, P | 1 |
| Feldman, AM | 1 |
| Ghali, JK; Tam, SW | 1 |
| Ferrer, E | 1 |
| Hutchinson, DJ; Nemerovski, C | 1 |
| Komai, Y; Palaniyandi, SS; Sukumaran, V; Thandavarayan, RA; Veeraveedu, PT; Watanabe, K; Yamaguchi, K | 1 |
| Singh, M; Slawsky, MT; Valania, G | 1 |
| Chiong, JR; Jao, GT | 1 |
| Cantillo, DS; Comín Colet, J; Robledo, GG | 1 |
| Villabona, C | 1 |
| Fürstner, C; Gheorghiade, M; Kolkhof, P; Mondritzki, T; Sabbah, HN; Schaefer, S; Schmeck, C; Siedentop, H; Truebel, H | 1 |
| Elhassan, EA; Schrier, RW | 1 |
| Cyr, PL; Goss, TF; Hauptman, PJ; Krasa, HB; Olchanski, N; Slawsky, KA; Zimmer, C | 1 |
| Er, F; Fuhr, U; Gassanov, N; Nia, AM; Semmo, M; Semmo, N | 1 |
| Ambrosy, A; Gheorghiade, M; Goldsmith, SR | 1 |
| DeVita, MV; Michelis, MF; Vaghasiya, RP | 1 |
| Burnett, JC; Dihu, J; Gheorghiade, M; Grinfeld, L; Khan, S; Konstam, MA; Maggioni, AP; Ouyang, J; Pang, PS; Swedberg, K; Udelson, JE; Zannad, F | 1 |
| Stiefelhagen, P | 1 |
| Gheorghiade, M; Konstam, MA; Pang, PS | 1 |
| Ambrosy, AP; Burnett, J; Cook, T; Filippatos, G; Gheorghiade, M; Grinfeld, L; Konstam, M; Lan, G; Maggioni, A; Pang, PS; Schmidt, P; Swedberg, K; Traver, B; Udelson, J; Zannad, F | 1 |
| Gheorghiade, M; Pitt, B | 1 |
| Chiong, JR; Christian, R; Dasta, JF; Kim, S; Lin, J | 1 |
| Asanoi, H; Hori, M; Izumi, T; Matsuzaki, M; Tsutamoto, T | 1 |
| Fukunami, M; Hori, M; Izumi, T; Matsuzaki, M | 2 |
| Fujiki, H; Nakamura, S; Nakayama, S; Onogawa, T; Sakamoto, Y; Yamamura, Y | 1 |
| Burnett, JC; Costello-Boerrigter, LC | 1 |
| Bai, H; Li, L; Zhu, WL | 1 |
| Abe, H; Hasumi, E; Hirata, Y; Inajima, T; Iwata, H; Kinugawa, K; Nagai, R; Nishimura, G; Semba, H; Shiga, T; Takeda, N; Terada, Y; Uchino, Y; Yonenaga, A | 1 |
| Alemayehu, A; O'Connell, JB | 1 |
| Akahoshi, Y; Fujiki, H; Iwanaga, Y; Miyazaki, S; Morooka, H; Nakano, Y; Takase, T; Tamaki, Y | 1 |
| Blair, J; Burnett, JC; Gheorghiade, M; Grinfeld, L; Konstam, MA; Krasa, HB; Maggioni, AP; Ouyang, J; Pang, PS; Swedberg, K; Vaduganathan, M; Zannad, F; Zimmer, C | 1 |
| Inomata, T | 1 |
| Dabrowska, MD; Krysiak, R; Okopień, B | 1 |
| Butler, J; Gheorghiade, M; Greene, SJ; Harinstein, ME; Konstam, MA; Maggioni, AP; Subačius, H; Swedberg, K; Vaduganathan, M; Zannad, F | 1 |
| Fought, AJ; Gheorghiade, M; Konstam, MA; Kwasny, MJ; Maggioni, AP; Mentz, RJ; Shah, AN; Swedberg, K; Zannad, F | 1 |
| Ambrosy, AP; Butler, J; Gheorghiade, M; Greene, SJ; Konstam, MA; Maggioni, AP; Mentz, RJ; Nodari, S; Subacius, HP; Swedberg, K; Vaduganathan, M; Zannad, F | 1 |
| Dohi, K; Hoshino, K; Ichikawa, K; Ito, M; Kumagai, N; Machida, H; Nakajima, H; Nakamori, S; Nakamura, M; Nobori, T; Okamoto, S; Onishi, K; Sato, Y; Sugimoto, T; Sugiura, E; Watanabe, K; Yamada, T | 1 |
| Hatano, M; Imamura, T; Inaba, T; Kato, N; Kinugawa, K; Kyo, S; Maki, H; Minatsuki, S; Muraoka, H; Nagai, R; Shiga, T; Yao, A | 1 |
| Hashimoto, Y; Iwatsuka, R; Matsue, Y; Matsumura, A; Mizukami, A; Nagahori, W; Ohno, M; Seya, M; Suzuki, M | 1 |
| Ambrosy, AP; Fought, AJ; Gheorghiade, M; Goldsmith, SR; Greene, SJ; Konstam, MA; Kwasny, MJ; Lanfear, DE; Maggioni, AP; Sabbah, HN; Swedberg, K; Yancy, CW; Zannad, F | 1 |
| Bhatt, DL; Cavender, MA | 1 |
| Ambrosy, AP; Butler, J; Fonarow, GC; Gheorghiade, M; Konstam, MA; Maggioni, A; Mentz, RJ; Subacius, H; Swedberg, K; Vaduganathan, M; Zannad, F | 1 |
| Endo, M; Hatano, M; Hirata, Y; Imamura, T; Inaba, T; Kato, N; Kinugawa, K; Kyo, S; Maki, H; Nagai, R; Nishimura, T; Ono, M; Shiga, T; Yao, A | 1 |
| Dohi, K; Ito, M; Watanabe, K | 1 |
| Ambrosy, AP; Butler, J; Gheorghiade, M; Greene, SJ; Vaduganathan, M | 1 |
| Hatano, M; Imamura, T; Inaba, T; Kato, N; Kinugawa, K; Komuro, I; Kyo, S; Maki, H; Minatsuki, S; Muraoka, H; Shiga, T; Yao, A | 1 |
| Ambrosy, AP; Gheorghiade, M; Greene, SJ; Konstam, MA; Maggioni, AP; Mentz, RJ; Subačius, H; Swedberg, K; Vaduganathan, M | 1 |
| Horibata, Y; Murakami, T; Niwa, K | 1 |
| Adams, KF; Barbagelata, A; Elkayam, U; Gattis, WA; Gheorghiade, M; O'Connor, CM; Orlandi, C | 1 |
| Czerwiec, F; Gheorghiade, M; Kambayashi, J; Niazi, I; Orlandi, C; Ouyang, J; Zampino, M | 1 |
| Thibonnier, M | 1 |
| Adams, KF; Barbagelata, A; Benza, RL; Elkayam, U; Gattis, WA; Ghali, JK; Gheorghiade, M; Klapholz, M; McGrew, FA; O'Connor, CM; Orlandi, C; Ouyang, J | 1 |
| Francis, GS; Tang, WH | 1 |
| SoRelle, R | 1 |
| Doggrell, SA | 1 |
| Sanghi, P; Schwarz, ER; Uretsky, BF | 1 |
| Burnett, JC; Demets, D; Gheorghiade, M; Grinfeld, L; Konstam, MA; Maggioni, A; Orlandi, C; Swedberg, K; Udelson, JE; Zannad, F; Zimmer, C | 1 |
| Salam, AM | 1 |
| Golestaneh, L; Le Jemtel, TH; Talreja, A | 1 |
| Dunlap, ME; Ibrahim, OA | 1 |
| Gheorghiade, M; Orlandi, C; Zimmer, CA | 1 |
| Gheorghiade, M; Mebazaa, A; Teerlink, JR | 1 |
| Boerrigter, G; Burnett, JC; Costello-Boerrigter, LC; Orlandi, C; Ouyang, J; Smith, WB; Zimmer, CA | 1 |
| Bramer, SL; Hauptman, PJ; Mallikaarjun, S; Orlandi, C; Shoaf, SE; Udelson, J; Zimmer, C | 1 |
| Streefkerk, JO; van Zwieten, PA | 1 |
| Barbagelata, A; Gheorghiade, M; Orlandi, C; Rangasetty, UC; Uretsky, BF | 1 |
| Greenberg, A; Verbalis, JG | 1 |
| Berl, T; Czerwiec, FS; Gheorghiade, M; Gross, P; Orlandi, C; Schrier, RW; Verbalis, JG | 1 |
| Casscells, SW; Elkayam, U; Gheorghiade, M; Orlandi, C; Ouyang, J; Payvar, S; Stough, WG | 1 |
| Omland, T; Solberg, OG | 1 |
| Hood, VL; Rimmer, JM; Weise, WJ | 1 |
| Arici, M; Kirkpantur, A; Ozkan, C | 1 |
| Burnett, JC; Cook, T; Gheorghiade, M; Grinfeld, L; Konstam, MA; Maggioni, AP; Orlandi, C; Ouyang, J; Swedberg, K; Udelson, JE; Zannad, F; Zimmer, C | 2 |
| Ali, F; Ghali, JK; Guglin, M; Vaitkevicius, P | 1 |
| Bolignano, D; Buemi, M; Campo, S; Coppolino, G; Criseo, M; Romeo, A | 1 |
| Fujiki, H; Miyazaki, T; Mori, T; Nakamura, S; Yamamura, Y | 1 |
| Rossi, GP | 1 |
| Flores, E; Ibrahim, H; Katz, S; Konstam, MA; Koshkarian, G; Kronenberg, MW; McGrew, FA; O'Brien, T; Orlandi, C; Udelson, JE; Zimmer, C | 1 |
| Fujiki, H; Sato, O; Yamamura, Y | 1 |
| Adams, KF; Bayram, M; Gheorghiade, M; Lloyd-Jones, D; Oconnor, CM; Orlandi, C; Ouyang, J; Rossi, J; Shin, DD; Stough, WG; Udelson, JE | 1 |
| Aizawa, Y; Kodama, M; Ma, M; Palaniyandi, SS; Suzuki, K; Veeraveedu, PT; Watanabe, K; Yamaguchi, K | 1 |
| Kumar, S; Mather, PJ; Rubin, S; Whellan, DJ | 1 |
| Horowitz, J; Kaski, JC; McMurray, JJ; Recio-Mayoral, A; Remme, WJ; van Veldhuisen, DJ | 1 |
| Głuszek, J; Olszewski, W | 1 |
| Greenberg, A | 1 |
| Aizawa, Y; Kodama, M; Ma, M; Palaniyandi, SS; Veeraveedu, PT; Watanabe, K; Yamaguchi, K | 1 |
| Greenberg, BH; Mehra, MR; Rockman, HA | 1 |
| Hobbs, RE; Tang, WH | 1 |
| Achtari Jeanneret, L; Barras-Moret, AC; Carron, P; Deriaz-Chessex, S; Donzé, J; Fournier, Y; Gachoud, D; Moix, PA; Monti, M; Rossier, A; Wilson, P | 1 |
| Schweiger, TA; Zdanowicz, MM | 1 |
| Balding, LC; Burrell, LM; Johnston, CI; Naitoh, M; Risvanis, J | 1 |
75 review(s) available for tolvaptan and Heart Failure
| Article | Year |
|---|---|
Vaptans for oedematous and hyponatraemic disorders in childhood: A systematic literature review.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Child; Diuretics; Heart Failure; Humans; Hyponatremia; Sodium; Tolvaptan | 2022 |
Benefits of tolvaptan on early dyspnea relief in patients with acute heart failure: A meta-analysis.
Topics: Antidiuretic Hormone Receptor Antagonists; Dyspnea; Heart Failure; Humans; Tolvaptan | 2022 |
Comment on: Benefits of tolvaptan on early dyspnea relief in patients with acute heart failure: A meta-analysis.
Topics: Acute Disease; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Dyspnea; Heart Failure; Humans; Tolvaptan | 2023 |
Tolvaptan for water retention in heart failure: a systematic review.
Topics: Databases, Factual; Heart Failure; Humans; Tolvaptan; Water; Water-Electrolyte Balance | 2023 |
Tolvaptan in reversing worsening acute heart failure: A systematic review and meta-analysis.
Topics: Acute Disease; Antidiuretic Hormone Receptor Antagonists; Dyspnea; Heart Failure; Humans; Prognosis; Tolvaptan | 2019 |
Advent of New perioperative care for fluid management after cardiovascular surgery: A review of current evidence.
Topics: Antidiuretic Hormone Receptor Antagonists; Cardiac Surgical Procedures; Heart Failure; Humans; Perioperative Care; Postoperative Period; Tolvaptan | 2020 |
Tolvaptan add-on therapy in patients with acute heart failure: A systematic review and meta-analysis.
Topics: Acute Disease; Antidiuretic Hormone Receptor Antagonists; Diuretics; Dose-Response Relationship, Drug; Drug Therapy, Combination; Heart Failure; Humans; Randomized Controlled Trials as Topic; Tolvaptan | 2020 |
Vasopressin and Vasopressin Antagonists in Heart Failure.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Glycopeptides; Heart Failure; Hemodynamics; Humans; Hyponatremia; Receptors, Vasopressin; Tolvaptan; Vasopressins | 2017 |
Use of tolvaptan vs. furosemide in older patients with heart failure : Meta-analysis of randomized controlled trials.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diuretics; Furosemide; Heart Failure; Humans; Randomized Controlled Trials as Topic; Tolvaptan | 2018 |
Effects of Tolvaptan in patients with acute heart failure: a systematic review and meta-analysis.
Topics: Acute Disease; Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Biomarkers; Dyspnea; Female; Heart Failure; Humans; Male; Middle Aged; Odds Ratio; Randomized Controlled Trials as Topic; Recovery of Function; Sodium; Time Factors; Tolvaptan; Treatment Outcome; Weight Loss | 2017 |
Effects and safety of oral tolvaptan in patients with congestive heart failure: A systematic review and network meta-analysis.
Topics: Administration, Oral; Adult; Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Female; Heart Failure; Humans; Male; Middle Aged; Tolvaptan | 2017 |
Tolvaptan for Heart Failure in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Glomerular Filtration Rate; Heart Failure; Humans; Renal Insufficiency, Chronic; Tolvaptan | 2018 |
Hemodynamic and Hormonal Effects of Tolvaptan for Heart Failure.
Topics: Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diuresis; Diuretics; Female; Heart Failure; Hemodynamics; Hospitalization; Humans; Japan; Length of Stay; Male; Middle Aged; Patient Discharge; Prognosis; Tolvaptan | 2019 |
Molecular mechanisms and clinical features of heart failure.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; C-Reactive Protein; Disasters; Earthquakes; Female; Heart Failure; Humans; Japan; Male; Mice; Serum Amyloid P-Component; Tolvaptan | 2018 |
Effects of Tolvaptan on Volume Overload in Patients with Heart Failure.
Topics: Diuretics; Dose-Response Relationship, Drug; Drug Administration Schedule; Heart Failure; Humans; Randomized Controlled Trials as Topic; Tolvaptan; Treatment Outcome; Water-Electrolyte Balance | 2018 |
Update of acute and long-term tolvaptan therapy.
Topics: Acute Disease; Antidiuretic Hormone Receptor Antagonists; Chronic Disease; Heart Failure; Humans; Japan; Time Factors; Tolvaptan | 2019 |
Efficacy of tolvaptan for chronic heart failure: Study protocol for a systematic review of randomized controlled trial.
Topics: Antidiuretic Hormone Receptor Antagonists; Body Weight; Chronic Disease; Heart Failure; Humans; Quality of Life; Randomized Controlled Trials as Topic; Research Design; Sodium; Tolvaptan; Urine | 2019 |
Tolvaptan for Volume Management in Heart Failure.
Topics: Antidiuretic Hormone Receptor Antagonists; Clinical Trials as Topic; Diuretics; Heart Failure; Humans; Practice Guidelines as Topic; Tolvaptan; Treatment Outcome | 2019 |
Vasopressin receptor antagonists: from pivotal trials to current practice.
Topics: Antidiuretic Agents; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Heart Failure; Hormone Antagonists; Humans; Tolvaptan | 2014 |
Therapeutic potential of vasopressin-receptor antagonists in heart failure.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzamides; Benzazepines; Body Water; Clinical Trials as Topic; Disease Models, Animal; Heart Failure; Homeostasis; Humans; Hyponatremia; Morpholines; Pyrroles; Receptors, Vasopressin; Spiro Compounds; Tolvaptan; Ventricular Remodeling | 2014 |
[Alternatives to conventional diuretic therapy in heart failure].
Topics: Acute Disease; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cardio-Renal Syndrome; Clinical Trials as Topic; Dopamine; Drug Resistance; Drug Substitution; Drug Therapy, Combination; Furosemide; Heart Failure; Hemofiltration; Humans; Multicenter Studies as Topic; Saline Solution, Hypertonic; Sodium Potassium Chloride Symporter Inhibitors; Stroke Volume; Tolvaptan | 2014 |
[Organ-protection therapy. A new therapeutic approach for acute heart failure?].
Topics: Acute Disease; Amides; Benzazepines; Cardio-Renal Syndrome; Dobutamine; Fumarates; Heart Failure; Humans; Hydrazones; Inflammation; Kaplan-Meier Estimate; Multicenter Studies as Topic; Natriuretic Peptide, Brain; Prognosis; Pyridazines; Randomized Controlled Trials as Topic; Recombinant Proteins; Relaxin; Simendan; Therapies, Investigational; Tolvaptan | 2014 |
Novel diuretic strategies for the treatment of heart failure in Japan.
Topics: Antidiuretic Hormone Receptor Antagonists; Atrial Natriuretic Factor; Benzazepines; Diuretics; Heart Failure; Humans; Japan; Receptors, Vasopressin; Tolvaptan | 2014 |
Potential roles of vaptans in heart failure: experience from clinical trials and considerations for optimizing therapy in target patients.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Clinical Trials as Topic; Heart Failure; Humans; Hyponatremia; Prospective Studies; Tolvaptan; Vasopressins | 2014 |
The short-term and long-term effects of tolvaptan in patients with heart failure: a meta-analysis of randomized controlled trials.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Body Weight; Creatinine; Heart Failure; Humans; Hyponatremia; Potassium; Randomized Controlled Trials as Topic; Sodium; Time Factors; Tolvaptan | 2015 |
Tolvaptan in Patients Hospitalized With Acute Heart Failure: Rationale and Design of the TACTICS and the SECRET of CHF Trials.
Topics: Acute Disease; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Clinical Trials as Topic; Disease Management; Heart Failure; Hospitalization; Humans; Tolvaptan | 2015 |
Urine Aquaporin-2: A Promising Marker of Response to the Arginine Vasopressin Type-2 Antagonist, Tolvaptan in Patients with Congestive Heart Failure.
Topics: Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Benzazepines; Biomarkers; Heart Failure; Humans; Tolvaptan | 2016 |
Tolvaptan for Heart Failure, Systematic Review and Meta-Analysis of Trials.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Body Weight; Heart Failure; Humans; Mortality; Randomized Controlled Trials as Topic; Tolvaptan | 2016 |
Role of tolvaptan in acute decompensated heart failure.
Topics: Acute Disease; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cause of Death; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heart Failure; Humans; Male; Maximum Tolerated Dose; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Severity of Illness Index; Survival Rate; Tolvaptan; Treatment Outcome | 2008 |
Hyponatremia in heart failure.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Heart Failure; Humans; Hyponatremia; Prognosis; Sodium; Tolvaptan; Treatment Outcome; Vasopressins | 2009 |
Vasopressin and vasopressin antagonists in heart failure and hyponatremia.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heart Failure; Humans; Hyponatremia; Infusions, Intravenous; Male; Prognosis; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vasopressin; Risk Assessment; Survival Rate; Tolvaptan; Water-Electrolyte Imbalance | 2008 |
Pharmacology of vasopressin antagonists.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Benzodiazepines; Heart Failure; Humans; Morpholines; Pyrroles; Receptors, Vasopressin; Spiro Compounds; Tolvaptan | 2009 |
Treatment options for hyponatremia in heart failure.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Heart Failure; Humans; Hyponatremia; Inappropriate ADH Syndrome; Pyrroles; Sodium Potassium Chloride Symporter Inhibitors; Tolvaptan; Treatment Outcome | 2009 |
Management of heart failure: a brief review and selected update.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cardiotonic Agents; Diuretics; Heart Failure; Hemofiltration; Humans; Hydrazones; Natriuretic Peptide, Brain; Pacemaker, Artificial; Pyridazines; Simendan; Tolvaptan; Vasodilator Agents | 2008 |
Potential of endothelin-1 and vasopressin antagonists for the treatment of congestive heart failure.
Topics: Angiotensin II; Animals; Antidiuretic Agents; Antihypertensive Agents; Benzazepines; Biomarkers; Bosentan; Catecholamines; Drug Therapy, Combination; Endothelin-1; Heart Failure; Humans; Peptides, Cyclic; Renin-Angiotensin System; Sulfonamides; Sympathetic Nervous System; Tolvaptan; Treatment Outcome; Vasopressins | 2010 |
[Vasopressin receptor antagonists and heart failure].
Topics: Administration, Oral; Aged; Antidiuretic Hormone Receptor Antagonists; Azepines; Benzamides; Benzazepines; Controlled Clinical Trials as Topic; Female; Follow-Up Studies; Furosemide; Heart Failure; Hormone Antagonists; Humans; Hyponatremia; Indoles; Male; Morpholines; Platelet Aggregation Inhibitors; Pyrroles; Pyrrolidines; Sodium Potassium Chloride Symporter Inhibitors; Spiro Compounds; Time Factors; Tolvaptan | 2009 |
Vasopressin antagonists: Pharmacotherapy for the treatment of heart failure.
Topics: Azepines; Benzamides; Benzazepines; Heart Failure; Humans; Hyponatremia; Neurotransmitter Agents; Pyrroles; Tolvaptan; Vasopressins | 2010 |
The critical link of hypervolemia and hyponatremia in heart failure and the potential role of arginine vasopressin antagonists.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzamides; Benzazepines; Blood Pressure; Blood Volume; Female; Heart Failure; Humans; Hypertension; Hyponatremia; Male; Prevalence; Prognosis; Pyrroles; Receptors, Vasopressin; Tolvaptan; United States; Water-Electrolyte Balance | 2010 |
Tolvaptan for the treatment of hyponatremia and congestive heart failure.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Clinical Trials, Phase III as Topic; Drug Evaluation, Preclinical; Heart Failure; Humans; Hyponatremia; Tolvaptan | 2010 |
Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Blood Volume; Dose-Response Relationship, Drug; Drug Interactions; Heart Failure; Humans; Hyponatremia; Inappropriate ADH Syndrome; Liver Cirrhosis; Randomized Controlled Trials as Topic; Sodium; Tolvaptan | 2010 |
Treatment options for hyponatremia in heart failure.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Biomarkers; Blood Volume; Heart Failure; Humans; Hyponatremia; Inappropriate ADH Syndrome; Signal Transduction; Tolvaptan | 2010 |
Arginine vasopressin receptor antagonists (vaptans): pharmacological tools and potential therapeutic agents.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Clinical Trials as Topic; Drug Evaluation, Preclinical; Heart Failure; Humans; Hyponatremia; Receptors, Vasopressin; Sodium Potassium Chloride Symporter Inhibitors; Tolvaptan | 2010 |
Targeting hyponatremia and hemodynamics in acute decompensated heart failure: is there a role for vasopressin antagonists?
Topics: Acute Disease; Animals; Antidiuretic Hormone Receptor Antagonists; Benzamides; Benzazepines; Clinical Trials as Topic; Heart Failure; Hemodynamics; Humans; Hyponatremia; Prognosis; Pyrroles; Tolvaptan; Vasoconstriction; Vasopressins | 2011 |
Hyponatremia in acute decompensated heart failure: mechanisms, prognosis, and treatment options.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Biomarkers; Fluid Therapy; Heart Failure; Hormone Antagonists; Humans; Hyponatremia; Receptors, Vasopressin; Renin-Angiotensin System; Sodium; Tolvaptan; Treatment Outcome; Ventricular Dysfunction | 2010 |
[Hyponatremia in heart failure: physiopathology and pharmacological approach].
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzamides; Benzazepines; Body Water; Brain Edema; Demyelinating Diseases; Diuresis; Diuretics; Double-Blind Method; Heart Failure; Humans; Hyponatremia; Kidney; Multicenter Studies as Topic; Natriuresis; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vasopressin; Renin-Angiotensin System; Saline Solution, Hypertonic; Sympathetic Nervous System; Tolvaptan | 2010 |
[Vasopressin receptor antagonists: the vaptans].
Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Benzamides; Benzazepines; Calcium Signaling; Clinical Trials as Topic; Cyclic AMP; Double-Blind Method; Drug Therapy, Combination; Heart Failure; Humans; Hyponatremia; Inappropriate ADH Syndrome; Kidney Tubules, Collecting; Liver Cirrhosis; Morpholines; Multicenter Studies as Topic; Neoplasms; Pituitary Gland, Anterior; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vasopressin; Second Messenger Systems; Spiro Compounds; Tolvaptan; Vasopressins | 2010 |
Hyponatremia: diagnosis, complications, and management including V2 receptor antagonists.
Topics: Adaptation, Physiological; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Brain; Exercise; Heart Failure; Humans; Hyponatremia; Inappropriate ADH Syndrome; Liver Cirrhosis; Tolvaptan | 2011 |
Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH).
Topics: Antidiuretic Hormone Receptor Antagonists; Benzamides; Benzazepines; Diuretics; Heart Failure; Humans; Inappropriate ADH Syndrome; Liver Cirrhosis; Models, Biological; Morpholines; Pyrroles; Spiro Compounds; Tolvaptan; Water-Electrolyte Balance | 2011 |
Tolvaptan for the treatment of heart failure: a review of the literature.
Topics: Animals; Benzazepines; Clinical Trials as Topic; Consensus; Disease Models, Animal; Diuresis; Diuretics; Heart Failure; Humans; Hyponatremia; Tolvaptan; Toxicity Tests; Treatment Outcome | 2011 |
Tolvaptan for heart failure patients with volume overload.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diuretics; Edema, Cardiac; Heart Failure; Humans; Receptors, Vasopressin; Tolvaptan; Vasopressins | 2011 |
Hyponatremia, heart failure, and the role of tolvaptan.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diagnosis, Differential; Heart Failure; Humans; Hyponatremia; Prognosis; Tolvaptan; Treatment Outcome | 2012 |
[Tolvaptan (vasopressin receptor antagonist)].
Topics: Benzazepines; Cardiomyopathy, Dilated; Diuretics; Heart Failure; Humans; Tolvaptan; Vasopressins | 2011 |
[Hyponatremic hypervolemia in heart failure--the hot spot for vasopressin receptor antagonists?].
Topics: Antidiuretic Hormone Receptor Antagonists; Benzamides; Benzazepines; Diuretics; Heart Failure; Humans; Hyponatremia; Hypovolemia; Morpholines; Pyrroles; Spiro Compounds; Tolvaptan | 2012 |
The disconnect between phase II and phase III trials of drugs for heart failure.
Topics: Animals; Benzazepines; Cardiovascular Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Evidence-Based Medicine; Heart Failure; Humans; Hydrazones; Natriuretic Peptide, Brain; Patient Readmission; Patient Selection; Pyridazines; Pyridines; Risk Assessment; Risk Factors; Simendan; Tetrazoles; Time Factors; Tolvaptan; Treatment Outcome; Xanthines | 2013 |
Vasopressin receptor antagonists in heart failure.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Heart Failure; Humans; Pyrroles; Randomized Controlled Trials as Topic; Tolvaptan | 2003 |
Tolvaptan (Otsuka).
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Clinical Trials as Topic; Diuretics; Heart Failure; Humans; Receptors, Vasopressin; Structure-Activity Relationship; Tolvaptan | 2004 |
Vasopressin antagonism: a future treatment option in heart failure.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Heart Failure; Humans; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Tolvaptan | 2005 |
Vasopressin antagonists in heart failure.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Diuretics; Heart Failure; Humans; Randomized Controlled Trials as Topic; Tolvaptan; Water-Electrolyte Balance | 2004 |
Combination pharmacologic therapies for heart failure: what next after angiotensin-converting enzyme inhibitors and beta-blockers?
Topics: Acetanilides; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Clinical Trials as Topic; Drug Therapy, Combination; Enzyme Inhibitors; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Mineralocorticoid Receptor Antagonists; Piperazines; Pyridines; Ranolazine; Tetrazoles; Tolvaptan; Vasodilator Agents | 2005 |
Role of vasopressin antagonists in the management of acute decompensated heart failure.
Topics: Acute Disease; Antidiuretic Hormone Receptor Antagonists; Azepines; Benzamides; Benzazepines; Heart Failure; Humans; Pyrroles; Stroke Volume; Tolvaptan; Treatment Outcome; Vasoconstriction; Vasopressins | 2005 |
Pharmacology of new agents for acute heart failure syndromes.
Topics: Acute Disease; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cardiotonic Agents; Clinical Trials as Topic; Endothelin Receptor Antagonists; Heart Failure; Humans; Hydrazones; Pyridazines; Pyridines; Simendan; Syndrome; Tetrazoles; Tolvaptan; Vasodilator Agents | 2005 |
Vasopressin receptor antagonists: pharmacological tools and potential therapeutic agents.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Drug Design; Heart Failure; Hormone Antagonists; Humans; Hypertension; Inappropriate ADH Syndrome; Indoles; Presynaptic Terminals; Pyrrolidines; Receptors, Vasopressin; Renal Artery; Sympathetic Nervous System; Synaptic Transmission; Tolvaptan; Vasoconstriction; Vasoconstrictor Agents | 2006 |
Tolvaptan: a selective vasopressin type 2 receptor antagonist in congestive heart failure.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Brain; Heart Failure; Humans; Receptors, Vasopressin; Tolvaptan | 2006 |
Vasopressin receptor antagonists.
Topics: Antidiuretic Hormone Receptor Antagonists; Azepines; Benzamides; Benzazepines; Clinical Trials as Topic; Diabetes Insipidus, Nephrogenic; Fibrosis; Heart Failure; Humans; Hyponatremia; Osmolar Concentration; Polycystic Kidney Diseases; Pyrroles; Receptors, Vasopressin; Sodium; Tolvaptan; United States; United States Food and Drug Administration; Vasopressins | 2006 |
[Arginine vasopressin antagonism--new treatment option in chronic heart failure].
Topics: Animals; Antidiuretic Agents; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Heart Failure; Humans; Nephrons; Prognosis; Pyrroles; Receptors, Vasopressin; Tolvaptan; Treatment Outcome; Vasoconstrictor Agents | 2007 |
Therapeutic potential of vasopressin receptor antagonists.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Heart Failure; Humans; Hyponatremia; Inappropriate ADH Syndrome; Liver Cirrhosis; Morpholines; Pyrroles; Receptors, Vasopressin; Spiro Compounds; Tolvaptan | 2007 |
Aquaretic agents: what's beyond the treatment of hyponatremia?
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diuresis; Diuretics; Heart Failure; Humans; Hyponatremia; Osmolar Concentration; Polycystic Kidney Diseases; Tolvaptan | 2007 |
Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.
Topics: Administration, Oral; Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Models, Animal; Diuresis; Diuretics; Dogs; Dose-Response Relationship, Drug; Heart Failure; Humans; Hyponatremia; Polycystic Kidney Diseases; Rats; Receptors, Vasopressin; Tolvaptan; Treatment Outcome | 2007 |
[Vasopressin V2-receptor antagonist, tolvaptan, for treatment of heart failure].
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Body Fluids; Clinical Trials as Topic; Diuresis; Heart Failure; Humans; Hyponatremia; Tolvaptan | 2007 |
Hyponatremia and vasopressin antagonism in congestive heart failure.
Topics: Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Chronic Disease; Clinical Trials as Topic; Diuretics; Heart Failure; Humans; Hyponatremia; Models, Biological; Pyrroles; Registries; Renin-Angiotensin System; Sodium; Tolvaptan; Treatment Outcome; Vasopressins | 2007 |
V2 receptor antagonism with tolvaptan in heart failure.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Clinical Trials as Topic; Diuretics; Heart Failure; Humans; Tolvaptan | 2007 |
[Vasopressin antagonists in treatment of hyponatremia].
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Heart Failure; Hormone Antagonists; Humans; Hyponatremia; Inappropriate ADH Syndrome; Liver Cirrhosis; Sodium Chloride; Tolvaptan; Water-Electrolyte Balance | 2007 |
Vasopressin receptor antagonists in heart failure.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Azepines; Benzamides; Benzazepines; Heart Failure; Humans; Pyrroles; Receptors, Vasopressin; Tolvaptan; Vasopressins | 2006 |
Vasopressin-receptor antagonists in heart failure.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Cardiovascular Agents; Chronic Disease; Heart Failure; Humans; Hyponatremia; Pyrroles; Receptors, Vasopressin; Tolvaptan | 2008 |
Vasopressin receptor antagonism--a therapeutic option in heart failure and hypertension.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Heart Failure; Humans; Hypertension; Morpholines; Receptors, Vasopressin; Spiro Compounds; Tolvaptan | 2000 |
78 trial(s) available for tolvaptan and Heart Failure
| Article | Year |
|---|---|
Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of OPC-61815, a Prodrug of Tolvaptan for Intravenous Administration, in Patients With Congestive Heart Failure - A Phase II, Multicenter, Double-Blind, Randomized, Active-Controlled Trial.
Topics: Administration, Intravenous; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Double-Blind Method; Heart Failure; Humans; Prodrugs; Sodium; Tolvaptan | 2022 |
Efficacy of tolvaptan on advanced chronic kidney disease with heart failure: a randomized controlled trial.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diuretics; Furosemide; Heart Failure; Humans; Renal Insufficiency, Chronic; Sodium; Tolvaptan; Water-Electrolyte Imbalance | 2022 |
Efficacy and safety of intravenous OPC-61815 compared with oral tolvaptan in patients with congestive heart failure.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Body Weight; Diuretics; Female; Heart Failure; Humans; Hyperkalemia; Male; Tolvaptan | 2022 |
Post-discharge haemodilution, congestion, and clinical outcomes among patients hospitalized for heart failure with reduced ejection fraction: results from the EVEREST trial.
Topics: Aftercare; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Female; Heart Failure; Hemodilution; Hospitalization; Humans; Male; Middle Aged; Patient Discharge; Stroke Volume; Tolvaptan; Treatment Outcome; Ventricular Function, Left | 2020 |
Diuretic Strategies for Loop Diuretic Resistance in Acute Heart Failure: The 3T Trial.
Topics: Administration, Oral; Aged; Chlorothiazide; Diuretics; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Furosemide; Heart Failure; Humans; Infusions, Intravenous; Male; Metolazone; Middle Aged; Prospective Studies; Retrospective Studies; Tolvaptan; Treatment Outcome | 2020 |
Impact of adjunctive tolvaptan on sympathetic activity in acute heart failure with preserved ejection fraction.
Topics: 3-Iodobenzylguanidine; Heart Failure; Humans; Stroke Volume; Tolvaptan; Ventricular Function, Left | 2020 |
Acute Kidney Function Declines in the Context of Decongestion in Acute Decompensated Heart Failure.
Topics: Acute Kidney Injury; Aged; Antidiuretic Hormone Receptor Antagonists; Biomarkers; Female; Glomerular Filtration Rate; Heart Failure; Humans; Kidney; Male; Middle Aged; Natriuretic Peptide, Brain; Prognosis; Stroke Volume; Tolvaptan | 2020 |
Tolvaptan vs. furosemide-based diuretic regimens in patients hospitalized for heart failure with hyponatremia (AQUA-AHF).
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diuretics; Furosemide; Heart Failure; Humans; Hyponatremia; Prospective Studies; Tolvaptan | 2020 |
Differences in pharmacological property between combined therapy of the vasopressin V2-receptor antagonist tolvaptan plus furosemide and monotherapy of furosemide in patients with hospitalized heart failure.
Topics: Aged; Aged, 80 and over; Antidiuretic Agents; Antidiuretic Hormone Receptor Antagonists; Blood Pressure; Body Weight; Drug Therapy, Combination; Echocardiography; Female; Furosemide; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Tolvaptan | 2020 |
Efficacy and safety of early ultrafiltration in patients with acute decompensated heart failure with volume overload: a prospective, randomized, controlled clinical trial.
Topics: Acute Disease; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; China; Female; Fluid Shifts; Heart Failure; Humans; Male; Middle Aged; Prospective Studies; Sodium Potassium Chloride Symporter Inhibitors; Time Factors; Tolvaptan; Torsemide; Treatment Outcome; Ultrafiltration; Urination; Weight Loss | 2020 |
Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunction.
Topics: Acute Disease; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diuresis; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Glomerular Filtration Rate; Heart Failure; Humans; Hyponatremia; Injections, Intravenous; Male; Renal Insufficiency; Retrospective Studies; Time Factors; Tolvaptan; Treatment Outcome | 2017 |
Prognostic importance of sodium level trajectory in acute heart failure.
Topics: Acute Disease; Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Biomarkers; Cause of Death; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heart Failure; Hospital Mortality; Humans; Hyponatremia; Japan; Male; Prognosis; Retrospective Studies; Sodium; Survival Rate; Time Factors; Tolvaptan | 2017 |
Mechanisms of Diuresis for Acute Decompensated Heart Failure by Tolvaptan.
Topics: Acute Disease; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Creatinine; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Electric Impedance; Female; Follow-Up Studies; Heart Failure; Humans; Hyponatremia; Male; Middle Aged; Prognosis; Renal Insufficiency; Retrospective Studies; Tolvaptan | 2017 |
Clinical utility of early use of tolvaptan in very elderly patients with acute decompensated heart failure.
Topics: Age Factors; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Female; Health Services for the Aged; Heart Failure; Humans; Japan; Length of Stay; Male; Prospective Studies; Renal Insufficiency; Risk Factors; Survival Analysis; Tolvaptan; Treatment Outcome | 2017 |
Effects of Additive Tolvaptan vs. Increased Furosemide on Heart Failure With Diuretic Resistance and Renal Impairment - Results From the K-STAR Study.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Diuretics; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Female; Furosemide; Heart Failure; Humans; Kidney Diseases; Male; Tolvaptan; Treatment Outcome | 2017 |
Effects of Tolvaptan Addition to Furosemide in Normo- and Hyponatremia Patients with Heart Failure and Chronic Kidney Disease Stages G3b-5: A Subanalysis of the K-STAR Study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Furosemide; Heart Failure; Humans; Hyponatremia; Kidney Failure, Chronic; Male; Potassium; Prospective Studies; Sodium; Sodium Potassium Chloride Symporter Inhibitors; Tolvaptan; Treatment Outcome | 2017 |
Comparison of two dosing methods for immediate administration of tolvaptan in acute decompensated heart failure.
Topics: Acute Disease; Aged; Antidiuretic Hormone Receptor Antagonists; Drug Administration Schedule; Female; Heart Failure; Hospitalization; Humans; Male; Time Factors; Tolvaptan; Treatment Outcome | 2018 |
Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial).
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Death, Sudden, Cardiac; Defibrillators, Implantable; Double-Blind Method; Female; Follow-Up Studies; Heart Failure; Hospital Mortality; Hospitalization; Humans; Incidence; Male; Risk Factors; Stroke Volume; Survival Rate; Tolvaptan; United States | 2018 |
Comparison of the effects of tolvaptan and furosemide on renal water and sodium excretion in patients with heart failure and advanced chronic kidney disease: a subanalysis of the K-STAR study.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Diuretics; Female; Furosemide; Heart Failure; Humans; Male; Middle Aged; Prospective Studies; Renal Elimination; Renal Insufficiency, Chronic; Sodium; Tolvaptan; Water | 2018 |
Different diuretic properties between tolvaptan and furosemide in congestive heart failure patients with diuretic resistance and renal impairment: a subanalysis of the K-STAR.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Biomarkers; Creatinine; Drug Resistance; Female; Follow-Up Studies; Furosemide; Heart Failure; Humans; Male; Prospective Studies; Renal Insufficiency; Sodium; Sodium Potassium Chloride Symporter Inhibitors; Time Factors; Tolvaptan; Treatment Outcome | 2019 |
Population pharmacokinetics of tolvaptan in healthy subjects and patients with hyponatremia secondary to congestive heart failure or hepatic cirrhosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cross-Over Studies; Double-Blind Method; Female; Heart Failure; Humans; Hyponatremia; Liver Cirrhosis; Male; Middle Aged; Models, Biological; Tolvaptan; Young Adult | 2013 |
Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cardiovascular Agents; Disease Progression; Double-Blind Method; Female; Heart Failure; Hematocrit; Hospitalization; Humans; Kidney Function Tests; Male; Middle Aged; Natriuretic Peptides; Outcome Assessment, Health Care; Prognosis; Renal Insufficiency; Stroke Volume; Survival Analysis; Tolvaptan | 2013 |
Association of low body temperature and poor outcomes in patients admitted with worsening heart failure: a substudy of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Body Temperature; Cardiovascular Agents; Disease Progression; Double-Blind Method; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Prognosis; Risk Assessment; Stroke Volume; Survival Analysis; Tolvaptan | 2013 |
Clinical effectiveness of tolvaptan in patients with acute decompensated heart failure and renal failure: design and rationale of the AQUAMARINE study.
Topics: Acute Disease; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diuretics; Drug Therapy, Combination; Furosemide; Glomerular Filtration Rate; Heart Failure; Humans; Japan; Natriuretic Peptide, Brain; Prospective Studies; Renal Insufficiency; Research Design; Tolvaptan | 2014 |
Population-based meta-analysis of hydrochlorothiazide pharmacokinetics.
Topics: Adult; Antihypertensive Agents; Benzazepines; Diuretics; Heart Failure; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Models, Biological; Renal Insufficiency; Tolvaptan; Young Adult | 2013 |
Acute heart failure volume control multicenter randomized (AVCMA) trial: comparison of tolvaptan and carperitide.
Topics: Acute Disease; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Atrial Natriuretic Factor; Benzazepines; Diuretics; Female; Heart Failure; Humans; Male; Middle Aged; Tolvaptan | 2013 |
Immediate administration of tolvaptan prevents the exacerbation of acute kidney injury and improves the mid-term prognosis of patients with severely decompensated acute heart failure.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease-Free Survival; Female; Follow-Up Studies; Heart Failure; Hospital Mortality; Humans; Male; Prospective Studies; Survival Rate; Time Factors; Tolvaptan | 2014 |
The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Epidemiologic Methods; Female; Heart Failure; Heart Rate; Hospitalization; Humans; Male; Prognosis; Stroke Volume; Tolvaptan | 2013 |
Efficacy and safety of tolvaptan in heart failure patients with volume overload.
Topics: Aged; Aged, 80 and over; Benzazepines; Female; Heart Failure; Humans; Japan; Male; Middle Aged; Product Surveillance, Postmarketing; Prospective Studies; Tolvaptan | 2014 |
Assessment of quality of life during long-term treatment of tolvaptan in refractory heart failure: design and rationale of the AQUA-TLV study.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Prospective Studies; Quality of Life; Time Factors; Tolvaptan; Treatment Outcome | 2014 |
Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure.
Topics: Adult; Aged; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Arginine Vasopressin; Benzazepines; Biomarkers; Disease-Free Survival; Female; Heart Failure; Humans; Male; Middle Aged; Survival Rate; Tolvaptan | 2014 |
Efficacy of tolvaptan added to furosemide in heart failure patients with advanced kidney dysfunction: a pharmacokinetic and pharmacodynamic study.
Topics: Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diuretics; Female; Furosemide; Heart Failure; Humans; Kidney Diseases; Male; Middle Aged; Tolvaptan | 2015 |
Long-term effects and prognosis in acute heart failure treated with tolvaptan: the AVCMA trial.
Topics: Acute Disease; Aged; Aged, 80 and over; Atrial Natriuretic Factor; Benzazepines; Creatinine; Female; Heart Failure; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prognosis; Tolvaptan | 2014 |
Vasopressin V2 receptor antagonist tolvaptan is effective in heart failure patients with reduced left ventricular systolic function and low blood pressure.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Atrial Natriuretic Factor; Benzazepines; Female; Heart Failure; Humans; Hypotension; Male; Middle Aged; Stroke Volume; Tolvaptan; Treatment Outcome; Ventricular Dysfunction, Left | 2015 |
Safety of add-on tolvaptan in patients with furosemide-resistant congestive heart failure complicated by advanced chronic kidney disease: a sub-analysis of a pharmacokinetics/ pharmacodynamics study.
Topics: Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Blood Pressure; Blood Urea Nitrogen; Creatinine; Diuretics; Drug Interactions; Female; Furosemide; Heart Failure; Humans; Male; Middle Aged; Pilot Projects; Renal Insufficiency, Chronic; Tolvaptan; Uric Acid | 2015 |
Echocardiographic characteristics of patients with acute heart failure requiring tolvaptan: a retrospective study.
Topics: Acute Disease; Aged; Benzazepines; Diuretics; Echocardiography; Female; Heart Failure; Humans; Male; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity; Tolvaptan; Treatment Outcome; Ventricular Dysfunction, Left | 2015 |
The Efficacy of Tolvaptan in Congestive Heart Failure Patients with and Without Hypoalbuminemia: A Pilot Study.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diuretics; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Heart Failure; Humans; Hypoalbuminemia; Male; Middle Aged; Pilot Projects; Prospective Studies; Serum Albumin; Tolvaptan; Urine Specimen Collection | 2015 |
Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure.
Topics: Acute Disease; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diuretics; Drug Therapy, Combination; Female; Furosemide; Heart Failure; Hospitalization; Humans; Male; Renal Insufficiency; Tolvaptan | 2016 |
Temporal Changes in Postdischarge Mortality Risk After Hospitalization for Heart Failure (from the EVEREST Trial).
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cause of Death; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Patient Discharge; Prospective Studies; Risk Assessment; Survival Rate; Tolvaptan; United States | 2016 |
Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Double-Blind Method; Female; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Osmolar Concentration; Predictive Value of Tests; Stroke Volume; Tolvaptan; Treatment Outcome | 2016 |
Clinical Effectiveness of Tolvaptan in Patients With Acute Heart Failure and Renal Dysfunction.
Topics: Acute Disease; Administration, Oral; Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diuresis; Dose-Response Relationship, Drug; Female; Glomerular Filtration Rate; Heart Failure; Humans; Male; Prospective Studies; Renal Insufficiency; Tolvaptan; Treatment Outcome | 2016 |
Effect of tolvaptan on acute heart failure with hyponatremia--a randomized, double blind, controlled clinical trial.
Topics: Acute Disease; Administration, Oral; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Double-Blind Method; Female; Follow-Up Studies; Heart Failure; Humans; Hyponatremia; Male; Middle Aged; Sodium; Tolvaptan; Treatment Outcome | 2016 |
Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST Trial.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cause of Death; Double-Blind Method; Dyspnea; Female; Health Status; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Patient Discharge; Patient Readmission; Predictive Value of Tests; Prospective Studies; Quality of Life; Recovery of Function; Risk Factors; Stroke Volume; Surveys and Questionnaires; Time Factors; Tolvaptan; Treatment Outcome; Ventricular Function, Left | 2016 |
Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure.
Topics: Acute Disease; Aged; Aged, 80 and over; Benzazepines; Biomarkers; Decision Support Techniques; Diuresis; Diuretics; Female; Furosemide; Heart Failure; Hemoglobins; Humans; Kaplan-Meier Estimate; Kidney; Male; Middle Aged; Patient Readmission; Predictive Value of Tests; Reproducibility of Results; Risk Assessment; Risk Factors; Time Factors; Tolvaptan; Treatment Outcome; Xanthines | 2016 |
Administration of tolvaptan with reduction of loop diuretics ameliorates congestion with improving renal dysfunction in patients with congestive heart failure and renal dysfunction.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Body Weight; Creatinine; Female; Heart Failure; Humans; Japan; Kidney; Kidney Function Tests; Male; Middle Aged; Prospective Studies; Sodium; Sodium Potassium Chloride Symporter Inhibitors; Tolvaptan | 2017 |
Prognostic impact of early treatment with tolvaptan in patients with acute heart failure and renal dysfunction.
Topics: Acute Disease; Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Comorbidity; Early Medical Intervention; Female; Glomerular Filtration Rate; Heart Failure; Hospitalization; Humans; Kidney Function Tests; Male; Middle Aged; Prognosis; Renal Insufficiency; Tolvaptan; Treatment Outcome | 2016 |
Efficacy and Safety of Tolvaptan in Patients Hospitalized With Acute Heart Failure.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Double-Blind Method; Dyspnea; Female; Heart Failure; Humans; Kidney Function Tests; Male; Middle Aged; Prospective Studies; Tolvaptan | 2017 |
Tolvaptan Reduces the Risk of Worsening Renal Function in Patients With Acute Decompensated Heart Failure and Preserved Left Ventricular Ejection Fraction - Prospective Randomized Controlled Study.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Creatinine; Diuretics; Female; Heart Failure; Humans; Kidney Diseases; Male; Middle Aged; Stroke Volume; Tolvaptan; Urea; Ventricular Function, Left; Young Adult | 2017 |
Short-Term Effects of Tolvaptan in Patients With Acute Heart Failure and Volume Overload.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Double-Blind Method; Dyspnea; Female; Heart Failure; Humans; Male; Middle Aged; Tolvaptan; Water-Electrolyte Imbalance | 2017 |
Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program.
Topics: Aged; Aged, 80 and over; Benzazepines; Double-Blind Method; Female; Heart Failure; Hospitalization; Humans; Internationality; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Revascularization; Pacemaker, Artificial; Prospective Studies; Tolvaptan; Vasopressins | 2008 |
Pharmacotherapy of acute and chronic heart failure: part 2.
Topics: Acute Disease; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Heart Failure; Humans; Male; Prognosis; Prospective Studies; Risk Assessment; Severity of Illness Index; Survival Rate; Tolvaptan; Treatment Outcome | 2009 |
Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Progression; Epidemiologic Methods; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Patient Readmission; Prognosis; Tolvaptan; Treatment Outcome; Weight Gain | 2009 |
Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cardiovascular Agents; Cause of Death; Female; Heart Failure; Humans; Male; Middle Aged; Patient Readmission; Stroke Volume; Tolvaptan | 2010 |
Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure.
Topics: Adolescent; Adult; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cardiotonic Agents; Heart Failure; Humans; Hyponatremia; Length of Stay; Sodium; Tolvaptan | 2011 |
Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Female; Heart Failure; Humans; Male; Middle Aged; Tolvaptan | 2011 |
Effects of tolvaptan on volume overload in Japanese patients with heart failure: results of a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Topics: Adult; Aged; Antidiuretic Hormone Receptor Antagonists; Asian People; Benzazepines; Body Weight; Diuretics; Double-Blind Method; Drug Therapy, Combination; Edema, Cardiac; Female; Furosemide; Heart Failure; Humans; Male; Middle Aged; Potassium; Sodium; Tolvaptan; Young Adult | 2011 |
Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study).
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Body Weight; Diuretics; Double-Blind Method; Edema, Cardiac; Female; Heart Failure; Humans; Male; Middle Aged; Potassium; Sodium; Tolvaptan | 2011 |
Efficacy and safety of tolvaptan in heart failure patients with sustained volume overload despite the use of conventional diuretics: a phase III open-label study.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Asian People; Benzazepines; Blood Urea Nitrogen; Body Weight; Creatinine; Diuretics; Edema, Cardiac; Female; Heart Failure; Humans; Male; Potassium; Sodium; Tolvaptan | 2011 |
[The efficacy and safety of tolvaptan on treating heart failure patients with hyponatremia].
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Blood Pressure; Body Weight; Double-Blind Method; Heart Failure; Humans; Hyponatremia; Sodium; Tolvaptan | 2011 |
Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cardiovascular Agents; Diuretics; Double-Blind Method; Drug Therapy, Combination; Female; Furosemide; Heart Failure; Humans; Hypotension; Male; Middle Aged; Renal Insufficiency; Sodium; Tolvaptan; Treatment Outcome | 2012 |
Prognostic value of monocyte count in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial).
Topics: Angiotensin-Converting Enzyme Inhibitors; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cardiotonic Agents; Digoxin; Double-Blind Method; Follow-Up Studies; Heart Failure; Hospital Mortality; Humans; Inpatients; Kaplan-Meier Estimate; Leukocyte Count; Monocytes; Prognosis; Prospective Studies; Stroke Volume; Survival Rate; Tolvaptan | 2012 |
Predictive value of low relative lymphocyte count in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.
Topics: Aged; Benzazepines; Female; Follow-Up Studies; Heart Failure; Humans; Inpatients; Kaplan-Meier Estimate; Lymphocyte Count; Male; Middle Aged; Predictive Value of Tests; Prognosis; Regression Analysis; Stroke Volume; Tolvaptan; Vasopressins | 2012 |
Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients--association between non-responders and chronic kidney disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Blood Urea Nitrogen; Creatine; Diabetes Insipidus, Nephrogenic; Diuretics; Drug Monitoring; Female; Heart Failure; Humans; Hypovolemia; Logistic Models; Male; Middle Aged; Osmolar Concentration; Potassium; Predictive Value of Tests; Renal Insufficiency, Chronic; Sensitivity and Specificity; Sodium; Tolvaptan; Ultrasonography; Urine; Young Adult | 2013 |
Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Cause of Death; Female; Follow-Up Studies; Heart Failure; Humans; Inpatients; Kaplan-Meier Estimate; Male; Middle Aged; Prognosis; Stroke Volume; Survival Rate; Tolvaptan; United States | 2013 |
Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial.
Topics: Aged; Aged, 80 and over; Benzazepines; Clinical Protocols; Double-Blind Method; Europe; Europe, Eastern; Female; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Internationality; Male; Middle Aged; North America; Patient Selection; Prospective Studies; South America; Survival Rate; Tolvaptan; Treatment Outcome; Vasopressins | 2013 |
Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) t
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Blood Pressure; Dose-Response Relationship, Drug; Female; Heart Failure; Humans; Inpatients; Kaplan-Meier Estimate; Male; Middle Aged; Prognosis; Proportional Hazards Models; Stroke Volume; Survival Rate; Systole; Tolvaptan; Treatment Outcome; United States | 2013 |
Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Disease Progression; Double-Blind Method; Heart Failure; Hospitalization; Humans; Patient Selection; Prospective Studies; Receptors, Vasopressin; Research Design; Tolvaptan | 2003 |
Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Body Weight; Chronic Disease; Diuretics; Double-Blind Method; Edema, Cardiac; Female; Furosemide; Heart Failure; Humans; Hyponatremia; Male; Middle Aged; Osmolar Concentration; Sodium; Tolvaptan; Treatment Outcome; Urinalysis; Water-Electrolyte Balance | 2003 |
Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.
Topics: Ambulatory Care; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cardiovascular Agents; Diuretics; Double-Blind Method; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Tolvaptan; Ventricular Dysfunction, Left; Weight Loss | 2004 |
Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST).
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Body Weight; Double-Blind Method; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Hypokalemia; Placebos; Quality of Life; Research Design; Stroke Volume; Survival Rate; Tolvaptan; Treatment Outcome; Urination; Ventricular Dysfunction, Left | 2005 |
Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cross-Over Studies; Diuretics; Female; Furosemide; Heart Failure; Hemodynamics; Humans; Kidney; Male; Middle Aged; Placebos; Potassium; Sodium; Tolvaptan; Urination; Vasopressins; Water; Water-Electrolyte Balance | 2006 |
Comparison of two doses and dosing regimens of tolvaptan in congestive heart failure.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heart Failure; Humans; Male; Middle Aged; Tolvaptan; Treatment Outcome | 2005 |
Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Area Under Curve; Benzazepines; Double-Blind Method; Female; Heart Failure; Humans; Hyponatremia; Inappropriate ADH Syndrome; Liver Cirrhosis; Male; Middle Aged; Sodium; Tolvaptan | 2006 |
Comparison of 60-day mortality in hospitalized heart failure patients with versus without hypothermia.
Topics: Benzazepines; Female; Heart Failure; Hospitalization; Humans; Hypothermia; Male; Middle Aged; Retrospective Studies; Tolvaptan | 2006 |
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.
Topics: Administration, Oral; Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Blood Urea Nitrogen; Body Weight; Cardiovascular Agents; Creatinine; Double-Blind Method; Female; Heart Failure; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Quality of Life; Sodium; Tolvaptan | 2007 |
Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cardiovascular Agents; Diuretics; Double-Blind Method; Drug Therapy, Combination; Female; Furosemide; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Tolvaptan | 2007 |
Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction.
Topics: Administration, Oral; Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Blood Pressure; Dilatation, Pathologic; Double-Blind Method; Female; Heart Failure; Humans; Male; Middle Aged; Receptors, Vasopressin; Systole; Tolvaptan; Ventricular Function, Left; Ventricular Remodeling | 2007 |
Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial.
Topics: Aged; Benzazepines; Female; Heart Failure; Humans; Hyponatremia; Male; Middle Aged; Receptors, Vasopressin; Retrospective Studies; Sodium; Survival Rate; Tolvaptan; Treatment Outcome | 2007 |
203 other study(ies) available for tolvaptan and Heart Failure
| Article | Year |
|---|---|
Effect of oral tolvaptan for 1 year in patients with functional mitral regurgitation.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diuretics; Female; Heart Failure; Hospitalization; Humans; Male; Mitral Valve Insufficiency; Tolvaptan; Treatment Outcome | 2022 |
Peak Lag Between Plasma Vasopressin and Urine Aquaporin-2 Following Cardiac Surgery.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Arginine Vasopressin; Biomarkers; Body Fluids; Cardiac Surgical Procedures; Female; Heart Failure; Hemodynamics; Humans; Kidney; Male; Middle Aged; Postoperative Care; Prospective Studies; Tolvaptan; Vasopressins | 2021 |
Initiation and long-term use of tolvaptan for patients with worsening heart failure through hospital and clinic cooperation.
Topics: Glomerular Filtration Rate; Heart Failure; Hospitalization; Hospitals; Humans; Tolvaptan | 2021 |
Temporal trends in tolvaptan use after revision of national heart failure guidelines in Japan.
Topics: Acute Disease; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Female; Heart Failure; Hospital Mortality; Humans; Japan; Male; Prospective Studies; Risk Factors; Tolvaptan | 2021 |
Clinical features and long-term prognosis of patients with congestive heart failure taking tolvaptan: a comparison of patients with preserved and reduced left ventricular ejection fraction.
Topics: Female; Heart Failure; Humans; Male; Prognosis; Retrospective Studies; Stroke Volume; Tolvaptan; Ventricular Function, Left | 2022 |
Right ventricular contractility affects the clinical efficacy of add-on tolvaptan following hospitalization for heart failure in patients with significant tricuspid regurgitation.
Topics: Aged; Aged, 80 and over; Heart Failure; Hospitalization; Humans; Middle Aged; Natriuretic Peptide, Brain; Stroke Volume; Tolvaptan; Treatment Outcome; Tricuspid Valve Insufficiency; Ventricular Function, Left | 2022 |
Efficacy and safety of tolvaptan in acute heart failure patients during long-distance transportation.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Blood Pressure; Female; Heart Failure; Heart Rate; Humans; Intensive Care Units; Japan; Male; Middle Aged; Retrospective Studies; Tolvaptan; Transportation of Patients; Walking | 2022 |
Cost-Effectiveness of long-term tolvaptan administration for chronic heart failure treatment in Japan.
Topics: Aged; Cost-Benefit Analysis; Heart Failure; Humans; Japan; Meta-Analysis as Topic; Quality-Adjusted Life Years; Systematic Reviews as Topic; Tolvaptan | 2022 |
Effectiveness and Safety of Tolvaptan in Patients with Aortic Stenosis.
Topics: Antidiuretic Hormone Receptor Antagonists; Aortic Valve Stenosis; Benzazepines; Heart Failure; Humans; Retrospective Studies; Tolvaptan | 2022 |
Impact of tolvaptan on improvement of tricuspid regurgitation and right ventricular dimension in patients with right-sided heart failure.
Topics: Echocardiography; Heart Failure; Heart Ventricles; Humans; Tolvaptan; Tricuspid Valve Insufficiency | 2022 |
Efficacy and Safety of Combination Therapy with Tolvaptan and Furosemide in Children with Nephrotic Syndrome and Refractory Edema: A Prospective Interventional Study.
Topics: Child; Child, Preschool; Diuretics; Drug Therapy, Combination; Edema; Furosemide; Heart Failure; Humans; Male; Nephrotic Syndrome; Prospective Studies; Tolvaptan | 2022 |
Suitable Dose of Long-Term Tolvaptan to Reduce Heart Failure Rehospitalizations.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Cohort Studies; Drug Administration Schedule; Female; Heart Failure; Humans; Japan; Kaplan-Meier Estimate; Male; Patient Readmission; Registries; ROC Curve; Sodium Potassium Chloride Symporter Inhibitors; Tolvaptan | 2022 |
Simple Score to Predict Treatment Response to Low-Dose Tolvaptan in Patients with Heart Failure.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Heart Failure; Humans; Retrospective Studies; Tolvaptan | 2022 |
Tolerability of the Intravenously Administered Tolvaptan Prodrug, OPC-61815, in Patients With Congestive Heart Failure Who Have Difficulty With, or Are Incapable of, Oral Intake (TRITON-HF) - A Phase III, Multicenter, Open-Label Trial.
Topics: Antidiuretic Hormone Receptor Antagonists; Dyspnea; Edema; Heart Failure; Humans; Prodrugs; Tolvaptan | 2022 |
Innovative clinical pathway shortened the length of hospital stay and prevented readmission in patients with acute decompensated heart failure.
Topics: Acute Disease; Aged; Critical Pathways; Heart Failure; Humans; Length of Stay; Patient Readmission; Tolvaptan | 2022 |
Early initiation of tolvaptan is associated with early discharge in patients with heart failure regardless of age.
Topics: Activities of Daily Living; Aged; Antidiuretic Hormone Receptor Antagonists; Heart Failure; Humans; Patient Discharge; Tolvaptan | 2022 |
Stereoselective interaction of tolvaptan with amiodarone under racemic metabolic impact by CYP3A5 genotypes in heart failure patients.
Topics: Amiodarone; Cytochrome P-450 CYP3A; Genotype; Heart Failure; Humans; Immunosuppressive Agents; Tolvaptan | 2022 |
Impact of Goreisan upon aquaporin-2-incorporated aquaresis system in patients with congestive heart failure.
Topics: Aquaporin 2; Benzazepines; Diuretics; Heart Failure; Humans; Tolvaptan | 2023 |
Letter by Nakagawa, et al. Regarding Article, "Simple Score to Predict Treatment Response to Low-Dose Tolvaptan in Patients with Heart Failure".
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Heart Failure; Humans; Tolvaptan | 2022 |
Reply to Letter Regarding Article, "Simple Score to Predict Treatment Response to Low-Dose Tolvaptan in Patients with Heart Failure".
Topics: Antidiuretic Hormone Receptor Antagonists; Heart Failure; Humans; Tolvaptan | 2022 |
Impact of SGLT2 inhibitors on old age patients with heart failure and chronic kidney disease.
Topics: Aged; Glomerular Filtration Rate; Heart Failure; Humans; Prospective Studies; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Tolvaptan | 2023 |
Trends in tolvaptan prescription and the association between hypernatremia and aging in tolvaptan-treated patients in Japan: Real-world data mining using Japanese databases.
Topics: Aged; Aging; Antidiuretic Hormone Receptor Antagonists; Data Mining; East Asian People; Heart Failure; Humans; Hypernatremia; Japan; Tolvaptan | 2023 |
Combination of tolvaptan and valsartan improves cardiac and renal functions in doxorubicin-induced heart failure in mice.
Topics: Animals; bcl-2-Associated X Protein; Caspase 3; Doxorubicin; Fibrosis; Heart Failure; Inflammation; Kidney; Kidney Diseases; Mice; Stroke Volume; Tolvaptan; Valsartan; Ventricular Function, Left | 2022 |
Impact of tolvaptan add-on treatment on patients with heart failure requiring long-term congestion management: A retrospective cohort study using a medical claim database in Japan.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Furosemide; Heart Failure; Hospital Mortality; Humans; Japan; Retrospective Studies; Sodium Potassium Chloride Symporter Inhibitors; Tolvaptan | 2023 |
The efficacy of tolvaptan for heart failure in chronic kidney disease: A protocol for systematic review and meta-analysis.
Topics: Heart Failure; Humans; Meta-Analysis as Topic; Renal Insufficiency, Chronic; Research Design; Review Literature as Topic; Systematic Reviews as Topic; Tolvaptan | 2022 |
Early Commencement and Long-Term Continuation of Tolvaptan Treatment Attenuate Functional Impairment of Renal Vasopressin V2 Receptors and Improve Clinical Outcomes in Patients with Heart Failure.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Heart Failure; Humans; Receptors, Vasopressin; Tolvaptan; Vasopressins | 2023 |
Predictors of Poor Very Early Diuretic Response and Effectiveness of Early Tolvaptan in Symptomatic Acute Heart Failure.
Topics: Diuretics; Furosemide; Heart Failure; Humans; Retrospective Studies; Sodium Potassium Chloride Symporter Inhibitors; Tolvaptan | 2023 |
Impact of urine cyclic AMP relative to plasma arginine vasopressin on response to tolvaptan in patients with chronic kidney disease and heart failure.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Cyclic AMP; Heart Failure; Humans; Male; Prospective Studies; Renal Insufficiency, Chronic; Tolvaptan | 2023 |
Impact of the time-to-target rate of urine volume concept on the outcome of acute decompensated heart failure.
Topics: Acute Disease; Diuretics; Heart Failure; Hospital Mortality; Humans; Natriuretic Peptide, Brain; Retrospective Studies; Tolvaptan | 2023 |
Total body fluid is the factor that affects the pharmacokinetics of tolvaptan, and its efficacy, in acute worsening heart failure patients.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Body Fluids; Heart Failure; Humans; Tolvaptan | 2023 |
Tolvaptan's Association with Low Risk of Acute Kidney Injury in Patients with Advanced Chronic Kidney Disease and Acute Decompensated Heart Failure.
Topics: Acute Disease; Acute Kidney Injury; Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Furosemide; Heart Failure; Humans; Male; Renal Insufficiency, Chronic; Retrospective Studies; Tolvaptan | 2023 |
Risk factors of readmission and the impact of outpatient management in heart failure patients: A national study in Japan.
Topics: Diabetes Mellitus; Female; Heart Failure; Humans; Japan; Outpatients; Patient Readmission; Risk Factors; Sodium Potassium Chloride Symporter Inhibitors; Tolvaptan | 2023 |
Effects of door-to-tolvaptan time on short-term clinical outcome in patients with acute heart failure.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Heart Failure; Hospital Mortality; Humans; Male; Retrospective Studies; Tolvaptan | 2023 |
Effects of recombinant human brain natriuretic peptide combined with tolvaptan on cardiac and renal function and serum inflammatory factors in patients with severe heart failure.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Heart Failure; Humans; Kidney; Natriuretic Peptide, Brain; Retrospective Studies; Tolvaptan | 2023 |
A Prospective, Multicenter, Post-Marketing Surveillance Study to Evaluate the Safety and Effectiveness of Tolvaptan in Patients with Reduced, Preserved, and Mid-Range Ejection Fraction Heart Failure.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Heart Failure; Humans; Japan; Male; Middle Aged; Product Surveillance, Postmarketing; Prospective Studies; Quality of Life; Risk Assessment; Severity of Illness Index; Stroke Volume; Tolvaptan; Treatment Outcome; Ventricular Dysfunction, Left | 2019 |
Short-Term Efficacy and Safety of Tolvaptan in Patients with Left Ventricular Assist Devices.
Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Female; Heart Failure; Heart-Assist Devices; Humans; Hyponatremia; Male; Middle Aged; Retrospective Studies; Tolvaptan | 2020 |
Impact of CYP3A5 genotype on tolvaptan pharmacokinetics and their relationships with endogenous markers of CYP3A activity and serum sodium level in heart failure patients.
Topics: Aged; Aged, 80 and over; Alleles; Antidiuretic Hormone Receptor Antagonists; ATP Binding Cassette Transporter, Subfamily B; Cholesterol; Cytochrome P-450 CYP3A; Female; Genotype; Heart Failure; Humans; Hydroxycholesterols; Male; Sodium; Tolvaptan; Vitamin D | 2020 |
An enantiomeric quantitative LC-MS/MS method for tolvaptan and its monohydroxylates in human plasma using a reversed-phase separation procedure.
Topics: Antidiuretic Hormone Receptor Antagonists; Chromatography, Liquid; Cytochrome P-450 CYP3A; Heart Failure; Humans; Hydroxylation; Limit of Detection; Metabolic Clearance Rate; Reproducibility of Results; Stereoisomerism; Tandem Mass Spectrometry; Tolvaptan | 2020 |
Short-term effects of low-dose tolvaptan in acute decompensated heart failure patients with severe aortic stenosis: The LOHAS registry.
Topics: Antidiuretic Hormone Receptor Antagonists; Aortic Valve Stenosis; Benzazepines; Heart Failure; Humans; Registries; Tolvaptan | 2020 |
Renoprotective effect of tolvaptan in patients with new-onset acute heart failure.
Topics: Diuretics; Furosemide; Heart Failure; Humans; Retrospective Studies; Tolvaptan | 2020 |
Expression of aquaporin-2 in the collecting duct and responses to tolvaptan.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Biomarkers, Pharmacological; Diabetic Nephropathies; Heart Failure; Humans; Immunohistochemistry; Kidney Tubules, Collecting; Male; Middle Aged; Tolvaptan; Urinary Tract Infections | 2021 |
Protective effect of tolvaptan against cyclophosphamide-induced nephrotoxicity in rat models.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Antineoplastic Agents; Apoptosis; Cyclophosphamide; Cytokines; Heart Failure; Hyponatremia; Injections, Intraperitoneal; Kidney Function Tests; Lipid Peroxidation; Liver Cirrhosis; Male; Models, Animal; Oxidative Stress; Protective Agents; Rats; Receptors, Vasopressin; Renal Insufficiency; Tolvaptan | 2020 |
Tolvaptan-induced hypernatremia related to low serum potassium level accompanying high blood pressure in patients with acute decompensated heart failure.
Topics: Acute Disease; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Biomarkers; Blood Pressure; Female; Heart Failure; Hospitalization; Humans; Hypernatremia; Male; Potassium; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Tolvaptan; Treatment Outcome | 2020 |
For vaptans, as for life, balance is better.
Topics: Antidiuretic Hormone Receptor Antagonists; Heart Failure; Humans; Tolvaptan | 2021 |
[Retrospective Observational Study on Predictors of Body Weight and BNP Teduction in Cases of Tolvaptan Induction for Heart Failure].
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Body Weight; Female; Heart Failure; Humans; Male; Natriuretic Peptide, Brain; Retrospective Studies; ROC Curve; Sodium; Tolvaptan | 2021 |
Clinical effectiveness and adverse events associated with tolvaptan in patients above 90 years of age with acute decompensated heart failure.
Topics: Acute Disease; Age Factors; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Female; Follow-Up Studies; Heart Failure; Humans; Male; Retrospective Studies; Stroke Volume; Tolvaptan; Treatment Outcome | 2021 |
Long-term administration of tolvaptan ameliorates annual decline in estimated glomerular filtration rate in outpatients with chronic heart failure.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Chronic Disease; Glomerular Filtration Rate; Heart Failure; Humans; Outpatients; Retrospective Studies; Tolvaptan | 2021 |
Usefulness of Tolvaptan for the Postoperative Control After Kidney Transplantation in a Patient With Cardiac Hypofunction: A Case Report.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Cardiac Output, Low; Heart Failure; Humans; Kidney Failure, Chronic; Kidney Transplantation; Male; Myocardial Infarction; Postoperative Complications; Renal Dialysis; Tolvaptan | 2021 |
Characterization of tolvaptan response and its impact on the outcome for patients with heart failure.
Topics: Aftercare; Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Heart Failure; Humans; Male; Patient Discharge; Retrospective Studies; Tolvaptan | 2021 |
A cross-sectional survey of hospitalization and blood tests implementation status in patients who received tolvaptan under 75 years of age using a Japanese claims database.
Topics: Antidiuretic Hormone Receptor Antagonists; Chemical and Drug Induced Liver Injury; Cross-Sectional Studies; Databases, Factual; Female; Heart Failure; Hematologic Tests; Hospitalization; Humans; Hypernatremia; Japan; Liver Function Tests; Male; Middle Aged; Sodium; Tolvaptan | 2021 |
Heart failure: No early benefits of adjunct therapy with tolvaptan for acute heart failure.
Topics: Diuretics; Heart Failure; Humans; Tolvaptan | 2017 |
Tolvaptan, Is It a Trump to Worsening Renal Function?
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diuretics; Furosemide; Heart Failure; Humans; Renal Insufficiency, Chronic; Tolvaptan | 2017 |
An economic analysis of tolvaptan compared with fluid restriction among hospitalized patients with hyponatremia.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Decision Support Techniques; Fluid Therapy; Heart Failure; Hospitalization; Humans; Hyponatremia; Inappropriate ADH Syndrome; Intensive Care Units; Length of Stay; Models, Econometric; Patient Readmission; Severity of Illness Index; Sodium; Tolvaptan | 2017 |
Effects of Tolvaptan With or Without the Pre-Administration of Renin-Angiotensin System Blockers in Hospitalized Patients With Acute Decompensated Heart Failure.
Topics: Acute Disease; Aged; Angiotensin-Converting Enzyme Inhibitors; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Heart Failure; Humans; Male; Retrospective Studies; Tolvaptan; Treatment Outcome; Urination | 2017 |
Successful Treatment of Congestive Heart Failure Due to Severe Aortic Valve Stenosis With Low Dose Tolvaptan in Elderly Patients.
Topics: Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Aortic Valve Stenosis; Benzazepines; Dose-Response Relationship, Drug; Echocardiography; Female; Follow-Up Studies; Glomerular Filtration Rate; Heart Failure; Hemodynamics; Humans; Male; Retrospective Studies; Severity of Illness Index; Tolvaptan; Treatment Outcome; Urination | 2017 |
New Insights Into Tolvaptan Treatment and the Renin-Angiotensin-Aldosterone System.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heart Failure; Humans; Male; Middle Aged; Prognosis; Renin-Angiotensin System; Retrospective Studies; Severity of Illness Index; Tolvaptan; Treatment Outcome | 2017 |
Experience with long-term administration of tolvaptan to patients with acute decompensated heart failure.
Topics: Acute Disease; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Echocardiography; Female; Heart Failure; Hospital Mortality; Hospitalization; Humans; Male; Middle Aged; Mortality; Patient Readmission; Retrospective Studies; Time Factors; Tolvaptan | 2017 |
Use of tolvaptan in patients hospitalized for worsening chronic heart failure with severe hyponatremia: The initial experience at a single-center in Turkey.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cohort Studies; Female; Heart Failure; Humans; Hyponatremia; Male; Middle Aged; Retrospective Studies; Tolvaptan; Turkey | 2017 |
Chronic Kidney Disease Contributing to Dyspnea in Patients With Heart Failure.
Topics: Dyspnea; Heart Failure; Humans; Renal Insufficiency, Chronic; Tolvaptan | 2017 |
Efficacy and safety of the early use of V2 receptor antagonists in elderly patients with decompensated heart failure.
Topics: Age Factors; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Female; Follow-Up Studies; Heart Failure; Humans; Hyponatremia; Japan; Male; Middle Aged; Retrospective Studies; Risk Factors; Survival Rate; Time Factors; Tolvaptan; Treatment Outcome | 2018 |
Safety and Efficacy of Long-Term Use of Tolvaptan in Patients With Heart Failure and Chronic Kidney Disease.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Survival Rate; Time Factors; Tolvaptan; Treatment Outcome | 2017 |
Favorable effects of early tolvaptan administration in very elderly patients after repeat hospitalizations for acute decompensated heart failure.
Topics: Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Heart Failure; Humans; Injections, Intravenous; Male; Patient Readmission; Retrospective Studies; Tolvaptan; Treatment Outcome; Urination | 2018 |
Tolvaptan promotes urinary excretion of sodium and urea: a retrospective cohort study.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Biomarkers; Blood Pressure; Blood Urea Nitrogen; Creatinine; Female; Heart Failure; Humans; Male; Middle Aged; Osmolar Concentration; Polycystic Kidney, Autosomal Dominant; Renal Insufficiency, Chronic; Retrospective Studies; Tolvaptan | 2018 |
Effects of tolvaptan on urine output in hospitalized heart failure patients with hypoalbuminemia or proteinuria.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Biomarkers; Female; Heart Failure; Humans; Hypoalbuminemia; Male; Proteinuria; Tolvaptan; Urination | 2018 |
The relationship between the time until commencement of tolvaptan and the length of hospital stay in heart failure patients.
Topics: Acute Disease; Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Echocardiography; Female; Follow-Up Studies; Heart Failure; Humans; Length of Stay; Male; Retrospective Studies; Tolvaptan; Treatment Outcome | 2018 |
Good response to tolvaptan shortens hospitalization in patients with congestive heart failure.
Topics: Administration, Oral; Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Female; Heart Failure; Humans; Male; Retrospective Studies; Tolvaptan | 2018 |
Amiodarone-Induced Hyponatremia Masked by Tolvaptan in a Patient with an Implantable Left Ventricular Assist Device.
Topics: Adult; Amiodarone; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Delirium; Heart Failure; Heart-Assist Devices; Humans; Hyponatremia; Inappropriate ADH Syndrome; Male; Sodium Channel Blockers; Tolvaptan | 2017 |
Impact of chronic kidney disease on the diuretic response of tolvaptan in acute decompensated heart failure.
Topics: Acute Disease; Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Progression; Diuresis; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Glomerular Filtration Rate; Heart Failure; Humans; Male; Renal Insufficiency, Chronic; Retrospective Studies; Tolvaptan; Treatment Outcome | 2017 |
A diuretic-sparing strategy to facilitate deactivation of vasopressin secretion.
Topics: Acute Kidney Injury; Animals; Diuretics; Heart Failure; Humans; Rats, Wistar; Tolvaptan; Vasopressins | 2018 |
Utilization and budget impact of tolvaptan in the inpatient setting among patients with heart failure and hyponatremia.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Budgets; Databases, Factual; Female; Heart Failure; Hospital Costs; Hospitalization; Humans; Hyponatremia; Inpatients; Male; Middle Aged; Tolvaptan | 2018 |
Impact of Continuous Administration of Tolvaptan on Preventing Medium-Term Worsening Renal Function and Long-Term Adverse Events in Heart Failure Patients with Chronic Kidney Disease.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Creatinine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Glomerular Filtration Rate; Heart Failure; Humans; Kidney Function Tests; Male; Prognosis; Renal Insufficiency, Chronic; Retrospective Studies; Time Factors; Tolvaptan | 2018 |
Tolvaptan should be used very carefully in very elderly patients.
Topics: Aged; Benzazepines; Heart Failure; Humans; Tolvaptan | 2018 |
Tolvaptan Improves Prognosis in Responders with Acute Decompensated Heart Failure by Reducing the Dose of Loop Diuretics.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Glomerular Filtration Rate; Heart Failure; Humans; Hyponatremia; Japan; Male; Prognosis; Propensity Score; Retrospective Studies; Sodium Potassium Chloride Symporter Inhibitors; Survival Rate; Tolvaptan | 2018 |
Rapidity of Correction of Hyponatremia Due to Syndrome of Inappropriate Secretion of Antidiuretic Hormone Following Tolvaptan.
Topics: Adult; Aged; Antidiuretic Hormone Receptor Antagonists; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heart Failure; Humans; Hyponatremia; Inappropriate ADH Syndrome; Linear Models; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Severity of Illness Index; Sodium; Tolvaptan; Treatment Outcome | 2018 |
A case report with shock induced by tolvaptan in an elderly patient with congestive heart failure.
Topics: Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Heart Failure; Humans; Male; Shock; Tolvaptan | 2018 |
Novel Risk Score Efficiently Prevents Tolvaptan-Induced Hypernatremic Events in Patients With Heart Failure.
Topics: Aged; Creatinine; Female; Heart Failure; Humans; Hypernatremia; Incidence; Japan; Male; Middle Aged; Potassium; Sodium; Tolvaptan; Urea | 2018 |
Tolvaptan alleviates excessive fluid retention of nephrotic diabetic renal failure unresponsive to furosemide.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diabetic Nephropathies; Drug Resistance; Female; Furosemide; Heart Failure; Humans; Male; Middle Aged; Nephrotic Syndrome; Renal Insufficiency; Severity of Illness Index; Sodium Potassium Chloride Symporter Inhibitors; Time Factors; Tolvaptan; Treatment Outcome; Water-Electrolyte Balance | 2018 |
The effects of tolvaptan dose on cardiac mortality in patients with acute decompensated heart failure after hospital discharge.
Topics: Acute Disease; Administration, Oral; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cause of Death; Dose-Response Relationship, Drug; Echocardiography; Female; Follow-Up Studies; Heart Failure; Heart Ventricles; Humans; Japan; Male; Patient Discharge; Patient Readmission; Prognosis; Retrospective Studies; Stroke Volume; Survival Rate; Tolvaptan | 2018 |
Economic impact of tolvaptan treatment vs. fluid restriction based on real-world data among hospitalized patients with heart failure and hyponatremia.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Female; Fluid Therapy; Heart Failure; Humans; Hyponatremia; Length of Stay; Male; Middle Aged; Models, Economic; Tolvaptan | 2018 |
Vasopressin antagonism for decompensated right-sided heart failure.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Creatinine; Diuresis; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Retrospective Studies; Stroke Volume; Tolvaptan; Treatment Outcome; Ventricular Function, Right | 2019 |
Prognostic factors for long-term outcomes in acute decompensated heart failure patients under tolvaptan treatment.
Topics: Acute Disease; Aged; Antidiuretic Hormone Receptor Antagonists; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heart Failure; Humans; Japan; Male; Patient Readmission; Prognosis; Sodium; Stroke Volume; Survival Rate; Time Factors; Tolvaptan | 2019 |
A novel validated method for predicting the risk of re-hospitalization for worsening heart failure and the effectiveness of the diuretic upgrading therapy with tolvaptan.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus; Diuretics; Female; Heart Failure; Heart Rate; Hematocrit; Hemoglobins; Hospitalization; Humans; Male; Risk Factors; Tolvaptan; Uric Acid | 2018 |
Renoprotective effects of tolvaptan in hypertensive heart failure rats depend on renal decongestion.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Central Venous Pressure; Fibrosis; Heart Failure; Hemodynamics; Hypertension; Kidney Diseases; Kidney Medulla; Male; Protective Agents; Rats; Rats, Inbred Dahl; Sodium, Dietary; Stroke Volume; Tolvaptan; Ultrasonography; Vascular Resistance | 2019 |
Efficacy of Long-Term Treatment With Tolvaptan to Prolong the Time Until Dialysis Initiation in Patients With Chronic Kidney Disease and Heart Failure.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Comorbidity; Disease Progression; Female; Heart Failure; Hospitalization; Humans; Japan; Kidney Function Tests; Male; Outcome and Process Assessment, Health Care; Renal Dialysis; Renal Insufficiency, Chronic; Time; Time-to-Treatment; Tolvaptan | 2019 |
In Vivo and In Vitro Effects of Vasopressin V2 Receptor Antagonism on Myocardial Fibrosis in Rats.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Cardiomyopathies; Diet; Fibrosis; Heart Failure; Male; Rats; Rats, Sprague-Dawley; Receptors, Vasopressin; Sodium Chloride; Tolvaptan | 2019 |
Treatment of renal congestion by tolvaptan.
Topics: Animals; Benzazepines; Heart Failure; Kidney; Rats; Tolvaptan | 2019 |
Comparable effect of tolvaptan in heart failure patients with preserved or reduced ejection fraction.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Female; Heart Failure; Heart Rate; Hospitalization; Humans; Hypertension; Male; Middle Aged; Prognosis; Retrospective Studies; Stroke Volume; Tolvaptan; Ventricular Dysfunction, Left | 2020 |
Validated liquid chromatography coupled to tandem mass spectrometry method for simultaneous quantitation of tolvaptan and its five major metabolites in human plasma.
Topics: Blood Chemical Analysis; Chromatography, Liquid; Heart Failure; Humans; Tandem Mass Spectrometry; Time Factors; Tolvaptan | 2019 |
Clinical safety and efficacy of tolvaptan for acute phase therapy in patients with low-flow and normal-flow severe aortic stenosis.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Aortic Valve Stenosis; Female; Glomerular Filtration Rate; Heart Failure; Humans; Japan; Male; Retrospective Studies; Time Factors; Tolvaptan; Treatment Outcome; Urination | 2019 |
Real-World Effectiveness and Tolerability of Tolvaptan in Patients With Heart Failure - Final Results of the Samsca Post-Marketing Surveillance in Heart Failure (SMILE) Study.
Topics: Aged; Aged, 80 and over; Female; Follow-Up Studies; Heart Failure; Humans; Japan; Male; Product Surveillance, Postmarketing; Tolvaptan | 2019 |
Patient Selection for Tolvaptan Therapy Among Those With Chronic Kidney Disease and Heart Failure.
Topics: Antidiuretic Hormone Receptor Antagonists; Heart Failure; Humans; Patient Selection; Renal Insufficiency, Chronic; Tolvaptan | 2020 |
Hypernatremia induced by low-dose Tolvaptan in a Patient with refractory heart failure: A case report.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Dose-Response Relationship, Drug; Heart Failure; Humans; Hypernatremia; Male; Sodium; Stroke Volume; Tolvaptan | 2019 |
Efficacy and Safety of Tolvaptan in Patients More Than 90 Years Old With Acute Heart Failure.
Topics: Age Factors; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Comorbidity; Databases, Factual; Female; Health Status; Heart Failure; Humans; Incidence; Japan; Male; Prevalence; Recovery of Function; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Tolvaptan; Treatment Outcome | 2020 |
Adding High-Dose Spironolactone to Tolvaptan Improves Acute Decompensated Heart Failure Due to Obstructive Hypertrophic Cardiomyopathy and Aortic Stenosis: A Case Report.
Topics: Acute Disease; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Aortic Valve Stenosis; Cardiomyopathy, Hypertrophic; Drug Therapy, Combination; Dyspnea; Female; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Tolvaptan | 2019 |
Successful conversion from thiazide to tolvaptan in a patient with stage d heart failure and chronic kidney disease before heart transplantation.
Topics: Benzazepines; Dose-Response Relationship, Drug; Drug Substitution; Heart Failure; Heart Transplantation; Humans; Hyponatremia; Kidney Function Tests; Male; Middle Aged; Postoperative Complications; Preoperative Care; Renal Agents; Renal Insufficiency, Chronic; Severity of Illness Index; Stroke Volume; Time; Tolvaptan; Treatment Outcome; Trichlormethiazide | 2013 |
Tolvaptan increases serum sodium in pediatric patients with heart failure.
Topics: Adolescent; Benzazepines; Blood Pressure; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heart Failure; Humans; Hyponatremia; Infant; Infant, Newborn; Male; Retrospective Studies; Sodium; Tolvaptan; Treatment Outcome | 2013 |
Tolvaptan for the treatment of hyponatremia and hypervolemia in patients with congestive heart failure.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Blood Volume; Dose-Response Relationship, Drug; Heart Failure; Homeostasis; Humans; Hyponatremia; Kidney; Sodium; Tolvaptan; Treatment Outcome | 2013 |
The effects of tolvaptan on patients with severe chronic kidney disease complicated by congestive heart failure.
Topics: Aged; Benzazepines; Creatinine; Diuretics; Heart Failure; Humans; Male; Middle Aged; Osmolar Concentration; Renal Insufficiency, Chronic; Retrospective Studies; Tolvaptan | 2013 |
Renoprotective effect of vasopressin v2 receptor antagonist tolvaptan in Dahl rats with end-stage heart failure.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Benzazepines; Chemokine CCL2; Chemokine CCL5; Drug Evaluation, Preclinical; Epithelial-Mesenchymal Transition; Heart Failure; Kidney Cortex; Male; MAP Kinase Signaling System; NADPH Oxidases; Nephrosclerosis; NF-kappa B; Oxidative Stress; Podocytes; Rats; Rats, Inbred Dahl; rho-Associated Kinases; Superoxides; Tolvaptan; Tumor Necrosis Factor-alpha | 2013 |
A case with recovery of response to tolvaptan associated with remission of acute kidney injury and increased urine osmolality.
Topics: Acute Kidney Injury; Adolescent; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Female; Heart Failure; Humans; Osmolar Concentration; Tolvaptan | 2013 |
Hyponatremia in heart failure: time for a trial.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Clinical Trials as Topic; Heart Failure; Humans; Hyponatremia; Sodium Potassium Chloride Symporter Inhibitors; Tolvaptan | 2013 |
Experience of a vasopressin receptor antagonist, tolvaptan, under the unique indication in Japanese heart failure patients.
Topics: Antidiuretic Agents; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Heart Failure; Humans; Japan; Osmolar Concentration; Tolvaptan | 2013 |
Tolvaptan attenuates left ventricular fibrosis after acute myocardial infarction in rats.
Topics: Acute-Phase Reaction; Animals; Benzazepines; Disease Models, Animal; Drug Therapy, Combination; Fibrosis; Furosemide; Heart Failure; Heart Ventricles; Male; Myocardial Infarction; Rats; Rats, Wistar; Tolvaptan; Ventricular Dysfunction, Left; Ventricular Remodeling | 2013 |
Tolvaptan can improve clinical course in responders.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diuretics; Female; Heart Failure; Humans; Male; Middle Aged; Tolvaptan; Urine; Young Adult | 2013 |
Beneficial role of tolvaptan in the control of body fluids without reductions in residual renal function in patients undergoing peritoneal dialysis.
Topics: Adult; Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Body Fluids; Diuretics; Female; Heart Failure; Humans; Kidney; Kidney Failure, Chronic; Male; Middle Aged; Osmolar Concentration; Peritoneal Dialysis; Tolvaptan; Urine | 2013 |
Immediate and short-term use of tolvaptan for acute decompensated heart failure.
Topics: Acute Kidney Injury; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Female; Heart Failure; Humans; Male; Tolvaptan | 2014 |
Urine sodium excretion after tolvaptan administration is dependent upon baseline serum sodium levels: a possible explanation for the improvement of hyponatremia with scarce chance of hypernatremia by a vasopressin receptor antagonist.
Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diuretics; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heart Failure; Humans; Hypernatremia; Hyponatremia; Male; Middle Aged; Retrospective Studies; Sodium; Tolvaptan; Treatment Outcome | 2014 |
[Effectiveness of tolvaptan for postoperative heart failure in a patient with combined valvular disease and pulmonary hypertension].
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Heart Failure; Heart Valve Diseases; Humans; Hypertension, Pulmonary; Male; Middle Aged; Postoperative Complications; Tolvaptan | 2014 |
Use of tolvaptan in patients with hyponatremia due to heart failure: initial experience.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Female; Heart Failure; Humans; Hyponatremia; Male; Middle Aged; Tolvaptan | 2013 |
Efficacy of tolvaptan in patients hospitalized for heart failure with refractory hyponatremia. Clinical experience in daily practice.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Drug Resistance; Female; Heart Failure; Humans; Hyponatremia; Male; Middle Aged; Retrospective Studies; Tolvaptan; Water-Electrolyte Balance | 2013 |
Decongestive therapy and renal function in acute heart failure: time for a new approach?
Topics: Acute Disease; Benzazepines; Dopamine; Heart Failure; Humans; Kidney; Natriuretic Peptide, Brain; Tolvaptan; Ultrafiltration | 2014 |
[Multination clinical trials: what is the relevance and what are the lessons from across-country differences?].
Topics: Acute Coronary Syndrome; Adenosine; Americas; Benzazepines; Cardiovascular Agents; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Ethnicity; Europe; Female; Georgia (Republic); Heart Failure; Humans; Internationality; Male; Metoprolol; Multicenter Studies as Topic; Platelet Aggregation Inhibitors; Russia; Sample Size; Spironolactone; Ticagrelor; Ticlopidine; Tolvaptan | 2014 |
Awareness of the vasopressin system in heart failure.
Topics: Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Arginine Vasopressin; Benzazepines; Female; Heart Failure; Humans; Male; Tolvaptan | 2014 |
Cost-effectiveness of tolvaptan for euvolemic or hypervolemic hyponatremia.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Blood Volume; Cost-Benefit Analysis; Heart Failure; Hospitalization; Humans; Hyponatremia; Models, Economic; Probability; Quality-Adjusted Life Years; Republic of Korea; Tolvaptan | 2014 |
Case report: new treatment with Tolvaptan for heart failure after cardiac surgery.
Topics: Benzazepines; Diuretics; Heart Failure; Heart Valve Prosthesis Implantation; Humans; Male; Middle Aged; Mitral Valve Insufficiency; Tolvaptan; Treatment Outcome; Water-Electrolyte Imbalance | 2014 |
Blood urea nitrogen as a marker of the acute response to addition of tolvaptan to standard therapy in patients hospitalized for acute heart failure syndromes.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Biomarkers; Blood Urea Nitrogen; Female; Heart Failure; Hospitalization; Humans; Male; Syndrome; Tolvaptan | 2014 |
Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial).
Topics: Age Factors; Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Black or African American; Blood Pressure; Female; Glomerular Filtration Rate; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Natriuretic Peptides; Prognosis; Proportional Hazards Models; Renal Insufficiency; Risk Factors; Sex Factors; Stroke Volume; Systole; Tolvaptan; Treatment Outcome; Uric Acid; Ventricular Dysfunction, Left; White People | 2014 |
Effect of tolvaptan in patients with chronic kidney disease due to diabetic nephropathy with heart failure.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Benzazepines; Diabetic Nephropathies; Female; Heart Failure; Humans; Kidney; Male; Middle Aged; Nephrotic Syndrome; Retrospective Studies; Tolvaptan | 2014 |
Ratio of urine and blood urea nitrogen concentration predicts the response of tolvaptan in congestive heart failure.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Area Under Curve; Benzazepines; Biomarkers; Blood Urea Nitrogen; Female; Heart Failure; Hospitals, University; Humans; Male; Middle Aged; Patient Selection; Predictive Value of Tests; Prospective Studies; ROC Curve; Tokyo; Tolvaptan; Treatment Outcome; Urea; Urination; Young Adult | 2015 |
Tolvaptan in a pediatric patient with diuretic-resistant heart and kidney failure.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Child; Diuretics; Drug Resistance; Heart Failure; Humans; Male; Renal Insufficiency; Tolvaptan | 2015 |
Changes in serum potassium levels during hospitalization in patients with worsening heart failure and reduced ejection fraction (from the EVEREST trial).
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Biomarkers; Clinical Trials as Topic; Creatinine; Female; Follow-Up Studies; Heart Failure; Humans; Hyperkalemia; Hypokalemia; Inpatients; Kaplan-Meier Estimate; Life Expectancy; Male; Middle Aged; Potassium; Research Design; Risk Factors; Stroke Volume; Tolvaptan; Treatment Outcome | 2015 |
Effectiveness and adverse events of tolvaptan in octogenarians with heart failure. Interim analyses of Samsca Post-Marketing Surveillance In Heart faiLurE (SMILE study).
Topics: Age Factors; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Drinking; Female; Heart Failure; Humans; Hyponatremia; Incidence; Male; Middle Aged; Product Surveillance, Postmarketing; Prospective Studies; Thirst; Tolvaptan; Treatment Outcome | 2015 |
Octogenarian patients with heart failure. Commonly encountered in clinical practice but only a minority in clinical trials.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Female; Heart Failure; Humans; Male; Tolvaptan | 2015 |
The first case of levetiracetam-induced and tolvaptan-resistant hyponatremia.
Topics: Aged; Anticonvulsants; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Epilepsy; Heart Failure; Humans; Hyponatremia; Inappropriate ADH Syndrome; Levetiracetam; Male; Piracetam; Tolvaptan | 2015 |
Urine osmolarity predicts the body weight-reduction response to tolvaptan in chronic kidney disease patients: a retrospective, observational study.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diuretics; Female; Heart Failure; Humans; Kidney Function Tests; Liver Cirrhosis; Male; Middle Aged; Osmolar Concentration; Renal Insufficiency, Chronic; Retrospective Studies; ROC Curve; Tolvaptan; Urodynamics; Weight Loss | 2015 |
Oral vasopressin receptor antagonist tolvaptan in right heart failure due to pulmonary hypertension.
Topics: Administration, Oral; Adult; Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Drug Administration Schedule; Female; Furosemide; Heart Failure; Humans; Hypertension, Pulmonary; Male; Middle Aged; Outpatients; Prospective Studies; Tolvaptan; Treatment Outcome | 2015 |
Blood Urea Nitrogen/Creatinine Ratio and Response to Tolvaptan in Patients with Decompensated Heart Failure: A Retrospective Analysis.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Biopharmaceutics; Blood Urea Nitrogen; Creatinine; Female; Heart Failure; Humans; Male; Pilot Projects; Predictive Value of Tests; Retrospective Studies; ROC Curve; Tolvaptan; Treatment Outcome | 2015 |
Acute Renal Injury Induced by Hypersensitivity to Tolvaptan in an Elderly Patient with Congestive Heart Failure.
Topics: Acute Kidney Injury; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Blood Pressure; Drug Hypersensitivity; Female; Heart Failure; Humans; Receptors, Vasopressin; Tolvaptan | 2015 |
Clinical characteristics of responders to treatment with tolvaptan in patients with acute decompensated heart failure: Importance of preserved kidney size.
Topics: Acute Disease; Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Female; Glomerular Filtration Rate; Heart Failure; Humans; Japan; Kidney; Male; Middle Aged; Multivariate Analysis; Organ Size; Osmolar Concentration; Prospective Studies; Tolvaptan | 2016 |
Effects of Long-term Blockade of Vasopressin Receptor Types 1a and 2 on Cardiac and Renal Damage in a Rat Model of Hypertensive Heart Failure.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Models, Animal; Drug Therapy, Combination; Fibrosis; Gene Expression Regulation; Heart Failure; Heart Ventricles; Hemodynamics; Hypertension; Hypertrophy, Left Ventricular; Kidney; Kidney Diseases; Male; Piperidines; Quinolones; Rats, Inbred Dahl; Receptors, Vasopressin; Time Factors; Tolvaptan; Ventricular Function, Left; Ventricular Remodeling | 2015 |
Successful Treatment of Intractable Fluid Retention Using Tolvaptan After Treatment for Postoperative Mediastinitis in a Patient With a Left Ventricular Assist Device.
Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Female; Heart Failure; Heart-Assist Devices; Hemodynamics; Humans; Hyponatremia; Mediastinitis; Negative-Pressure Wound Therapy; Omentum; Postoperative Complications; Prosthesis Implantation; Tissue Transplantation; Tolvaptan; Treatment Outcome | 2015 |
Contrasting acute and chronic effects of tolvaptan on serum osmolality in the EVEREST trial.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Heart Failure; Hospitalization; Humans; Osmolar Concentration; Randomized Controlled Trials as Topic; Tolvaptan | 2016 |
Effects of tolvaptan on congestive heart failure complicated with chylothorax in a neonate.
Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Body Weight; Chylothorax; Female; Heart Failure; Humans; Hyponatremia; Infant, Newborn; Male; Radiography, Thoracic; Tolvaptan; Transposition of Great Vessels | 2015 |
Mid-Term Administration of Tolvaptan Improves Renal Function Accompanied by Dose-Reduction in Furosemide in Aquaporin-Defined Responders.
Topics: Antidiuretic Hormone Receptor Antagonists; Aquaporins; Arginine Vasopressin; Benzazepines; Diuretics; Furosemide; Heart Failure; Humans; Kidney Function Tests; Medication Therapy Management; Patient Selection; Tolvaptan | 2015 |
Clinical benefit of tolvaptan in patients with acute decompensated heart failure and chronic kidney disease.
Topics: Acute Disease; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Creatinine; Female; Follow-Up Studies; Glomerular Filtration Rate; Heart Failure; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Patient Readmission; Renal Insufficiency, Chronic; Retrospective Studies; Tolvaptan | 2016 |
Early use of V2 receptor antagonists is associated with a shorter hospital stay and reduction in in-hospital death in patients with decompensated heart failure.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Early Medical Intervention; Female; Heart Failure; Hemodynamics; Hospital Mortality; Humans; Japan; Kidney Function Tests; Length of Stay; Linear Models; Logistic Models; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; ROC Curve; Tolvaptan | 2016 |
Efficacy and safety of tolvaptan for pediatric patients with congestive heart failure. Multicenter survey in the working group of the Japanese Society of PEdiatric Circulation and Hemodynamics (J-SPECH).
Topics: Adolescent; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Blood Circulation; Child; Child, Preschool; Coronary Circulation; Female; Heart Failure; Hemodynamics; Humans; Infant; Japan; Male; Pediatrics; Retrospective Studies; Societies, Medical; Surveys and Questionnaires; Tolvaptan; Treatment Outcome | 2016 |
Efficacy of Tolvaptan in Patients with Volume Overload after Cardiac Surgery.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Body Water; Cardiac Surgical Procedures; Female; Heart Failure; Humans; Male; Middle Aged; Postoperative Complications; Retrospective Studies; Tolvaptan | 2015 |
Tolvaptan Prolongs Blockage of the Vasopressin Type II Receptor Over 24 Hours in Responders With Stage D Heart Failure.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Receptors, Vasopressin; Retrospective Studies; Severity of Illness Index; Time Factors; Tolvaptan | 2016 |
Aquaporin-2 is a potential biomarker for tolvaptan efficacy in decompensated heart failure complicated by diabetic nephrotic syndrome.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Benzazepines; Biomarkers; Diabetic Nephropathies; Female; Heart Failure; Humans; Nephrotic Syndrome; Tolvaptan; Treatment Outcome | 2016 |
Recovery from hyponatremia in acute phase is associated with better in-hospital mortality rate in acute heart failure syndrome.
Topics: Acute Disease; Age Factors; Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Female; Heart Failure; Hospital Mortality; Humans; Hyponatremia; Male; Myocardial Ischemia; Prognosis; Retrospective Studies; Sex Factors; Tolvaptan | 2016 |
Combination of Urinary Sodium/Creatinine Ratio and Plasma Brain Natriuretic Peptide Level Predicts Successful Tolvaptan Therapy in Patients With Heart Failure and Volume Overload.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Biomarkers; Creatinine; Diuresis; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heart Failure; Humans; Hyponatremia; Male; Natriuretic Peptide, Brain; Prognosis; Retrospective Studies; Sodium; Tolvaptan; Ventricular Pressure | 2016 |
In-Hospital Diuretic Agent Use and Post-Discharge Clinical Outcomes in Patients Hospitalized for Worsening Heart Failure: Insights From the EVEREST Trial.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cause of Death; Disease Progression; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Mortality; Patient Readmission; Proportional Hazards Models; Randomized Controlled Trials as Topic; Sodium Potassium Chloride Symporter Inhibitors; Tolvaptan; Treatment Outcome | 2016 |
Response Prediction and Influence of Tolvaptan in Chronic Heart Failure Patients Considering the Interaction of the Renin-Angiotensin-Aldosterone System and Arginine Vasopressin.
Topics: Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Body Mass Index; Female; Heart Failure; Humans; Male; Middle Aged; Prospective Studies; Renin-Angiotensin System; Tolvaptan; Treatment Outcome | 2016 |
Risk factors for hypernatremia in patients with short- and long-term tolvaptan treatment.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Dose-Response Relationship, Drug; Female; Heart Failure; Humans; Hypernatremia; Male; Middle Aged; Risk Factors; Tolvaptan | 2016 |
A Safety and Efficacy Study of Tolvaptan Following Open Heart Surgery in 109 Cases.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Body Weight; Cardiac Surgical Procedures; Female; Heart Failure; Humans; Male; Postoperative Care; Retrospective Studies; Tolvaptan; Treatment Outcome | 2016 |
Predictors for Tolvaptan Treatment and Future Perspectives.
Topics: Aldosterone; Antidiuretic Hormone Receptor Antagonists; Arginine; Benzazepines; Biomarkers; Diuresis; Dose-Response Relationship, Drug; Evidence-Based Medicine; Heart Failure; Humans; Predictive Value of Tests; Prognosis; Renin-Angiotensin System; Sensitivity and Specificity; Severity of Illness Index; Tolvaptan; Treatment Outcome; Vasopressins | 2016 |
Long-term administration of tolvaptan increases myocardial remodeling and mortality via exacerbation of congestion in mice heart failure model after myocardial infarction.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Models, Animal; Heart Failure; Lung Diseases; Male; Mice; Mice, Inbred C57BL; Mortality; Myocardial Infarction; Random Allocation; Time Factors; Tolvaptan; Ventricular Remodeling | 2016 |
Tolvaptan Improves the Long-Term Prognosis in Patients With Congestive Heart Failure With Preserved Ejection Fraction as Well as in Those With Reduced Ejection Fraction.
Topics: Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Arginine Vasopressin; Benzazepines; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Prognosis; Retrospective Studies; Stroke Volume; Tolvaptan | 2016 |
Tolvaptan Reduces Long-Term Total Medical Expenses and Length of Stay in Aquaporin-Defined Responders.
Topics: Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Arginine Vasopressin; Benzazepines; Female; Health Care Costs; Heart Failure; Humans; Length of Stay; Male; Middle Aged; Prognosis; Retrospective Studies; Stroke Volume; Tolvaptan | 2016 |
Tolvaptan in Acute Heart Failure: Time to Move On.
Topics: Antidiuretic Hormone Receptor Antagonists; Heart Failure; Humans; Tolvaptan | 2017 |
Who Needs Longer Tolvaptan Treatment?
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Female; Heart Failure; Humans; Male; Middle Aged; Product Surveillance, Postmarketing; Prospective Studies; Tolvaptan; Treatment Outcome | 2017 |
[Current options of treatment of hyponatremia].
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Europe; Heart Failure; Humans; Hyponatremia; Inappropriate ADH Syndrome; Liver Cirrhosis; Receptors, Vasopressin; Sodium; Tolvaptan; Vasopressins | 2016 |
Future Study With Tolvaptan in Acute Heart Failure.
Topics: Acute Disease; Antidiuretic Hormone Receptor Antagonists; Heart Failure; Humans; Tolvaptan | 2017 |
Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diuresis; Diuretics; Female; Heart Failure; Humans; Kidney; Male; Middle Aged; Osmolar Concentration; Renal Elimination; Renal Insufficiency, Chronic; Retrospective Studies; Sodium; Time Factors; Tolvaptan; Treatment Outcome; Urine; Urodynamics; Weight Loss | 2017 |
Predictability of tricuspid annular plane systolic excursion for the effectiveness of tolvaptan in patients with heart failure.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Echocardiography; Female; Heart Failure; Humans; Male; Middle Aged; Prognosis; ROC Curve; Systole; Tolvaptan; Tricuspid Valve; Tricuspid Valve Insufficiency; Water-Electrolyte Imbalance | 2017 |
Comparison of tolvaptan treatment between patients with the SIADH and congestive heart failure: a single-center experience.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Female; Heart Failure; Humans; Hyponatremia; Inappropriate ADH Syndrome; Male; Middle Aged; Retrospective Studies; Tolvaptan | 2018 |
Acute Heart Failure: Searching for a New Evident Truth.
Topics: Antidiuretic Hormone Receptor Antagonists; Heart Failure; Humans; Tolvaptan | 2017 |
Introduction: Vasopressin therapy.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Chronic Disease; Heart Failure; Humans; Hyponatremia; Sodium; Tolvaptan; Vasopressins | 2009 |
EVEREST study: Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan.
Topics: Acute Disease; Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cardiovascular Agents; Europe; Female; Heart Failure; Hospitalization; Humans; Hyponatremia; Male; Middle Aged; North America; Randomized Controlled Trials as Topic; Tolvaptan | 2008 |
The vaptans ante portas: a status report.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Heart Failure; Humans; Hyponatremia; Tolvaptan; Treatment Outcome; Vasopressins | 2009 |
Renal and anti-aldosterone actions of vasopressin-2 receptor antagonism and B-type natriuretic peptide in experimental heart failure.
Topics: Aldosterone; Animals; Benzazepines; Blood Pressure; Disease Models, Animal; Dogs; Drug Therapy, Combination; Glomerular Filtration Rate; Heart Failure; Male; Natriuretic Agents; Natriuretic Peptide, Brain; Receptors, Vasopressin; Renal Circulation; Tolvaptan; Water-Electrolyte Balance | 2010 |
Critical elements of clinical follow-up after hospital discharge for heart failure: insights from the EVEREST trial.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Confidence Intervals; Disease Progression; Female; Health Status; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Multivariate Analysis; Patient Compliance; Patient Discharge; Patient Readmission; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Risk Factors; Surveys and Questionnaires; Time Factors; Tolvaptan; Treatment Outcome; United States | 2010 |
Multinational trials: lost in translation?
Topics: Benzazepines; Clinical Trials as Topic; Heart Failure; Humans; International Cooperation; Tolvaptan; Translational Research, Biomedical; Treatment Outcome; United States | 2009 |
Tolvaptan: any evidence of efficacy in SIADH?
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Clinical Trials as Topic; Heart Failure; Humans; Inappropriate ADH Syndrome; Off-Label Use; Sodium; Tolvaptan | 2010 |
Differentiation of arginine vasopressin antagonistic effects by selective V2 versus dual V2/V1a receptor blockade in a preclinical heart failure model.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Blood Pressure; Cardiac Output; Cardiac Pacing, Artificial; Dogs; Heart Failure; Hemodynamics; Pacemaker, Artificial; Tolvaptan; Urodynamics; Vascular Resistance | 2011 |
Serum and urine responses to the aquaretic agent tolvaptan in hospitalized hyponatremic patients.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Blood Pressure; Diuretics; Heart Failure; Humans; Hyponatremia; Inappropriate ADH Syndrome; Osmolar Concentration; Sodium; Tolvaptan | 2012 |
[Heart and kidney failure combined. Trouble seldom comes alone].
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Combined Modality Therapy; Comorbidity; Diagnosis, Differential; Diuretics; Edema, Cardiac; General Adaptation Syndrome; Heart Failure; Humans; Hyperparathyroidism, Secondary; Iron; Kidney Failure, Chronic; Renin-Angiotensin System; Tolvaptan | 2011 |
Seeking new heights in acute heart failure syndromes: lessons from ASCEND and EVEREST.
Topics: Acute Disease; Benzazepines; Drug Approval; Heart Failure; Humans; Natriuretic Peptide, Brain; Randomized Controlled Trials as Topic; Syndrome; Tolvaptan; Treatment Outcome; Vasodilator Agents | 2013 |
A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial.
Topics: Benzazepines; Female; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Male; Neurotransmitter Agents; Patient Readmission; Prognosis; Randomized Controlled Trials as Topic; Receptors, Vasopressin; Retrospective Studies; Tolvaptan | 2012 |
Vasopressin V1 receptor-mediated aldosterone production as a result of selective V2 receptor antagonism: a potential explanation for the failure of tolvaptan to reduce cardiovascular outcomes in the EVEREST trial.
Topics: Aldosterone; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Heart Failure; Humans; Randomized Controlled Trials as Topic; Receptors, Vasopressin; Tolvaptan; Treatment Failure | 2011 |
Evaluation of costs associated with tolvaptan-mediated length-of-stay reduction among heart failure patients with hyponatremia in the US, based on the EVEREST trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzazepines; Comorbidity; Costs and Cost Analysis; Databases, Factual; Heart Failure; Hospital Costs; Humans; Hyponatremia; Length of Stay; Middle Aged; Monte Carlo Method; Outcome Assessment, Health Care; Tolvaptan; United States; Young Adult | 2012 |
Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Atrial Natriuretic Factor; Benzazepines; Blood Pressure; Body Weight; Chlorides; Disease Models, Animal; Diuretics; Dogs; Furosemide; Heart Failure; Kidney; Male; Potassium; Renin; Sodium; Tolvaptan | 2011 |
Controlling the flood gates: vaptans, furosemide and the quest for a renal protective diuresis.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diuretics; Female; Furosemide; Heart Failure; Heart Failure, Systolic; Humans; Kidney; Male; Sodium Potassium Chloride Symporter Inhibitors; Tolvaptan | 2011 |
Preliminary report of tolvaptan treatment in Japanese patients with heart failure.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Heart Failure; Humans; Japan; Male; Middle Aged; Tolvaptan | 2012 |
Chronic administration of oral vasopressin type 2 receptor antagonist tolvaptan exerts both myocardial and renal protective effects in rats with hypertensive heart failure.
Topics: Administration, Oral; Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Biomarkers; Blood Pressure; Disease Models, Animal; Disease Progression; Drug Administration Schedule; Heart Failure; Hormone Antagonists; Hypertension; Kidney; Kidney Diseases; Male; Myocardium; Natriuretic Peptides; Rats; Rats, Inbred Dahl; Receptors, Vasopressin; RNA, Messenger; Sodium Chloride, Dietary; Time Factors; Tolvaptan; Ultrasonography; Urination; Ventricular Dysfunction, Left; Ventricular Function, Left | 2012 |
Gender does not affect postdischarge outcomes in patients hospitalized for worsening heart failure with reduced ejection fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan [EVEREST] Trial).
Topics: Benzazepines; Double-Blind Method; Female; Follow-Up Studies; Heart Failure; Humans; Kaplan-Meier Estimate; Male; Patient Discharge; Prospective Studies; Randomized Controlled Trials as Topic; Receptors, Vasopressin; Retrospective Studies; Sex Factors; Stroke Volume; Survival Rate; Tolvaptan; Treatment Outcome | 2012 |
Short-term effects of low-dose tolvaptan on hemodynamic parameters in patients with chronic heart failure.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Body Fluids; Body Weight; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Pulmonary Circulation; Sodium Chloride Symporter Inhibitors; Sodium Potassium Chloride Symporter Inhibitors; Time Factors; Tolvaptan; Urine; Vascular Resistance | 2012 |
Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure in high-risk population.
Topics: Acute Disease; Aged; Aged, 80 and over; Benzazepines; Comparative Effectiveness Research; Creatinine; Diuresis; Diuretics; Female; Furosemide; Heart Failure; Humans; Hypernatremia; Kidney Function Tests; Male; Multivariate Analysis; Natriuretic Peptide, Brain; Prospective Studies; Renal Insufficiency; Time Factors; Tolvaptan; Urination | 2013 |
Hyponatremia and outcomes in patients with heart failure.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Disease Progression; Global Health; Heart Failure; Humans; Hyponatremia; Incidence; Prognosis; Sodium; Survival Rate; Tolvaptan | 2012 |
Are all clinical trial sites created equal?
Topics: Benzazepines; Female; Heart Failure; Humans; Male; Patient Selection; Tolvaptan; Vasopressins | 2013 |
Correction of hyponatremia by tolvaptan before left ventricular assist device implantation.
Topics: Adult; Benzazepines; Follow-Up Studies; Heart Failure; Heart-Assist Devices; Humans; Hyponatremia; Male; Sodium; Tolvaptan | 2012 |
Urine osmolality-guided tolvaptan therapy in decompensated heart failure.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diabetes Insipidus, Nephrogenic; Drug Monitoring; Female; Heart Failure; Humans; Male; Tolvaptan | 2013 |
Urine osmolality estimated using urine urea nitrogen, sodium and creatinine can effectively predict response to tolvaptan in decompensated heart failure patients.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Biomarkers; Chi-Square Distribution; Creatinine; Female; Heart Failure; Hormone Antagonists; Hospitalization; Humans; Male; Middle Aged; Models, Biological; Nitrogen; Osmolar Concentration; Retrospective Studies; Sodium; Time Factors; Tolvaptan; Treatment Outcome; Urea | 2013 |
Effect of the oral vasopressin receptor antagonist tolvaptan on congestive cardiac failure in a child with restrictive cardiomyopathy.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cardiomyopathy, Restrictive; Child; Heart Failure; Humans; Male; Tolvaptan; Treatment Outcome | 2014 |
[Heart failure. Can vasopressin antagonists improve the prognosis?].
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Clinical Trials, Phase II as Topic; Disease Progression; Heart Failure; Humans; Survival Rate; Tolvaptan; Water-Electrolyte Balance | 2003 |
Vasopressin receptor antagonists: will the "vaptans" fulfill their promise?
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Cardiovascular Agents; Heart Failure; Humans; Tolvaptan | 2004 |
New drug fights fluid build-up. Medication may relieve a common heart failure symptom.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diuretics; Heart Failure; Humans; Tolvaptan; Water-Electrolyte Balance; Water-Electrolyte Imbalance | 2004 |
Rofecoxib use increases acute myocardial infarction risk.
Topics: Aortic Aneurysm, Abdominal; Benzazepines; Cardiology; Cholesterol; Female; Heart Failure; Humans; Lactones; Male; Myocardial Infarction; Seasons; Sulfones; Tolvaptan | 2004 |
New heart failure drug shows promise.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Heart Failure; Humans; Tolvaptan | 2004 |
A new class of heart failure drugs? Tolvaptan could be a welcome helper for "water pills" and their potentially serious side effects.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Heart Failure; Humans; Tolvaptan | 2004 |
The therapeutic potential of vasopressin receptor antagonists in congestive heart failure.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Heart Failure; Humans; Randomized Controlled Trials as Topic; Receptors, Vasopressin; Tolvaptan | 2005 |
New drugs for prevention, relief. How you might benefit if 3 medications win FDA approval.
Topics: Acetanilides; Angina Pectoris; Benzazepines; Heart Failure; Humans; Obesity; Piperazines; Piperidines; Pyrazoles; Ranolazine; Rimonabant; Tolvaptan | 2005 |
Tolvaptan for hyponatremia.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Heart Failure; Humans; Hyponatremia; Inappropriate ADH Syndrome; Liver Cirrhosis; Patient Dropouts; Tolvaptan; Water-Electrolyte Balance | 2007 |
Tolvaptan for hyponatremia.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Blood Volume; Diuretics; Heart Failure; Humans; Hyponatremia; Inappropriate ADH Syndrome; Liver Cirrhosis; Tolvaptan | 2007 |
Climbing the mountain of acute decompensated heart failure: the EVEREST Trials.
Topics: Acute Disease; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cardiovascular Agents; Heart Failure; Humans; Tolvaptan | 2007 |
Arginine vasopressin receptor antagonists for heart failure: a winter climbing to the Everest's tip?
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Clinical Trials as Topic; Heart Failure; Humans; Receptors, Vasopressin; Seasons; Tolvaptan; Ventricular Remodeling | 2007 |
Effects of nonpeptide vasopressin V2 antagonist tolvaptan in rats with heart failure.
Topics: Aldosterone; Animals; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Arginine Vasopressin; Benzazepines; Cardiac Myosins; Diuretics; Heart; Heart Failure; Hemodynamics; Kidney; Male; Organ Size; Osmolar Concentration; Rats; Rats, Inbred Lew; Sodium; Tolvaptan | 2007 |
Clinical trials update from the European Society of Cardiology Congress in Vienna, 2007: PROSPECT, EVEREST, ARISE, ALOFT, FINESSE, Prague-8, CARESS in MI and ACUITY.
Topics: Abciximab; Acute Coronary Syndrome; Amides; Antibodies, Monoclonal; Benzazepines; Clinical Trials as Topic; Clopidogrel; Electrocardiography; Europe; Fumarates; Heart Diseases; Heart Failure; Hirudins; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptide Fragments; Probucol; Recombinant Proteins; Ticlopidine; Tolvaptan | 2007 |
Tolvaptan, an oral vasopressin V2 receptor antagonist for heart failure?
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Heart Failure; Humans; Randomized Controlled Trials as Topic; Receptors, Vasopressin; Tolvaptan; Treatment Outcome | 2007 |
Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure.
Topics: Aldosterone; Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Blood Pressure; Body Weight; Creatinine; Diuretics; Echocardiography; Furosemide; Heart Failure; Heart Rate; Male; Organ Size; Osmolar Concentration; Potassium; Rats; Rats, Inbred Lew; Renin; Sodium; Tolvaptan; Ventricular Remodeling | 2008 |
Highlights of the 2007 Scientific Meeting of the Heart Failure Society of America: Washington, DC, September 16-19, 2007.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Biomedical Research; Cardiac Pacing, Artificial; Female; Heart Failure; Humans; Male; Practice Guidelines as Topic; Sex Factors; Stem Cell Transplantation; Telemedicine; Tolvaptan | 2008 |
[Highlights 2007 in hospital-based internal medicine: the point of view from the chief residents].
Topics: Accidental Falls; Aged; Albuterol; Anemia; Anticoagulants; Antidiuretic Hormone Receptor Antagonists; Atrial Fibrillation; Attitude of Health Personnel; Benzazepines; Bronchitis, Chronic; Bronchodilator Agents; Cardiac Pacing, Artificial; Diabetes Mellitus; Endocarditis, Bacterial; Erythropoietin; Heart Failure; Heparin; Humans; Internal Medicine; Interprofessional Relations; Medical Staff, Hospital; Myocardial Infarction; Recombinant Proteins; Risk Management; Rosiglitazone; Salmeterol Xinafoate; Thiazolidinediones; Thromboembolism; Tolvaptan; Vasodilator Agents; Ventricular Dysfunction, Left; Workload | 2008 |